US20140238909A1 - Batch filtration system for preparation of sterile fluid for renal replacement therapy - Google Patents

Batch filtration system for preparation of sterile fluid for renal replacement therapy Download PDF

Info

Publication number
US20140238909A1
US20140238909A1 US14/269,076 US201414269076A US2014238909A1 US 20140238909 A1 US20140238909 A1 US 20140238909A1 US 201414269076 A US201414269076 A US 201414269076A US 2014238909 A1 US2014238909 A1 US 2014238909A1
Authority
US
United States
Prior art keywords
fluid
controller
batch
pump
container
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/269,076
Inventor
James M. Brugger
Jeffrey H. Burbank
Brian C. Green
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NxStage Medical Inc
Original Assignee
NxStage Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NxStage Medical Inc filed Critical NxStage Medical Inc
Priority to US14/269,076 priority Critical patent/US20140238909A1/en
Assigned to GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT reassignment GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT SECURITY INTEREST Assignors: NXSTAGE MEDICAL, INC.
Publication of US20140238909A1 publication Critical patent/US20140238909A1/en
Assigned to HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR AGENT reassignment HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR AGENT ASSIGNMENT OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Assignors: GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING AGENT
Assigned to NXSTAGE MEDICAL, INC. reassignment NXSTAGE MEDICAL, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: CAPITAL ONE, NATIONAL ASSOCIATION (AS SUCCESSOR BY MERGER TO HEALTHCARE FINANCIAL SOLUTIONS, LLC)
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654Dialysates therefor
    • A61M1/1656Apparatus for preparing dialysates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654Dialysates therefor
    • A61M1/1656Apparatus for preparing dialysates
    • A61M1/166Heating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654Dialysates therefor
    • A61M1/1656Apparatus for preparing dialysates
    • A61M1/1668Details of containers
    • A61M1/167Flexible packaging for solid concentrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654Dialysates therefor
    • A61M1/1656Apparatus for preparing dialysates
    • A61M1/1672Apparatus for preparing dialysates using membrane filters, e.g. for sterilising the dialysate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654Dialysates therefor
    • A61M1/1656Apparatus for preparing dialysates
    • A61M1/1674Apparatus for preparing dialysates using UV radiation sources for sterilising the dialysate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/288Priming
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/342Adding solutions to the blood, e.g. substitution solutions
    • A61M1/3455Substitution fluids
    • A61M1/3462Circuits for the preparation thereof
    • CCHEMISTRY; METALLURGY
    • C02TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02FTREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00Treatment of water, waste water, or sewage
    • C02F1/44Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/12General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit

Definitions

  • blood is drawn from a patient, passed through a filter, and returned to the patient.
  • fluids and electrolytes are exchanged in the filter between a dialysate and/or extracted from the blood by filtration.
  • One effect may be a net loss of fluid and electrolytes from the patient and/or exhaustion of dialysate, with a concomitant need for its replenishment, again depending on the type of treatment.
  • replacement fluid may be injected into the patient at a rate that matches a rate of loss, with an adjustment for a desired net change in the patient's fluid complement.
  • fresh dialysate is continuously circulated through the filter.
  • dialysate and/or replacement fluid is supplied from either of two sources: batches of fluid, typically in multiple bags, or a continuous source of water that is sterile-filtered and added to concentrated electrolytes to achieve the required dilution level. Because replacement fluid is injected directly into the patient, replacement fluid must be sterile. When either method is used to generate replacement fluid, there is a risk of contamination of the fluid. Contamination may occur, for example, at the point where bags of fluid are accessed (“spiked”) or at any connection in the fluid circuit linking the source to the patient.
  • Such therapies may require a large quantity of sterile fluid.
  • a typical way to provide the large quantity of replacement fluid is to provide multiple bags of replacement fluid, dialysate, or infusate.
  • the connection of these bags of fluid to an extracorporeal blood circuit there is a risk of touch-contamination resulting in the introduction of biological contaminants into the fluids.
  • methods of producing large volumes of dialysate from tap water are known, but each requires complex water purification and standardization equipment, since impurities and cleaning additives such as chlorine vary greatly in tap water from municipality to municipality and within a municipality over time. (See Twardowski U.S. Pat. Nos.
  • dialysate solution whether prepared online or prepackaged, while of the proper concentration for use as a sterile replacement fluid, never enters the patient's body. Instead, dialysate flows past a semipermeable membrane that permits ions to be exchanged across the membrane until a balance between their concentrations in blood and their concentrations in the dialysis is achieved. This is effective to remove impurities from the blood and to add missing electrolytes to the blood. Because it does not have to be infused, dialysate is less expensive than solutions prepared as replacement fluids, which are injected directly into a patient.
  • sterile replacement fluid or dialysate may be generated in batch form by sterile-filtering.
  • non-sterile fluid is passed through a filter prior to treatment to prepare a batch of replacement fluid. This process may be permitted to take any length of time because the rate of flow of non-sterile replacement fluid (or components thereof) through the filter is completely independent of the rate of consumption by the renal therapy. Because the filters used for sterile-filtering tend to be expensive, it may be desirable for such a batch process to employ a small filter for such filtration. Such a filter can have a flow capacity that is much lower than that required for real-time filtering of the replacement fluid (or components).
  • embodiments of inventions disclosed may be used to sterilize already-sterile fluid as a precaution against touch contamination.
  • Generally replacement fluid is heated before being infused into a patient. This is often accomplished by heating the fluid as it is being infused with a heater with sufficient heating capacity. The capacity of the heater must be matched to the mass flow of the fluid and the temperature rise required. In a batch preparation process, where a batch of fluid is prepared over a substantial period before use, a small heater may heat the replacement fluid over a long period of time. Insulation may be provided to prevent heat loss. An insulating outer container for the sterile replacement fluid may be provided.
  • the container may be an insulated box with room for one or more large disposable sterile bags of the type normally used for infusible fluids.
  • the preparation of warm sterile replacement fluid may be automated by a control process that permits a user to set up the fluids and other materials well in advance of a scheduled treatment. The process would ensure that the replacement fluid is sterilized and heated to the proper temperature when the treatment is to begin.
  • the automation process may be permit the user to select how far in advance of the treatment the preparation should be performed. This may be useful, for example, where a particular source of replacement fluid has proved to release more than a usual quantity of dissolved gases upon heating. Heating the replacement fluid and permitting it to settle for a time before it is used may allow gases to come out of solution and settle at the top of the batch vessel or vessels.
  • the automation process may be incorporated in the control functions of renal therapy machine.
  • FIG. 1 is a schematic illustration of a standalone/retrofit apparatus system for batch filtration of a sterile replacement fluid.
  • FIG. 2 is a flow chart illustrating an exemplary control procedure applicable to various embodiments of the invention including those of FIGS. 1 and 3 .
  • FIG. 3 is a schematic illustration of a blood treatment machine with an attached subsystem for batch preparation of sterile replacement fluid.
  • FIGS. 4A and 4B are illustrations of fluid filters that may be use in various embodiments of the invention.
  • FIG. 5 illustrates an exemplary blood treatment system with a filter used to sterilize and/or degas replacement fluid during treatment.
  • FIGS. 6-8 illustrate a blood treatment machine and cartridge providing various supporting mechanical features for the embodiment of FIG. 5 and further embodiments, including one in which a quality of replacement fluid is sensed before infusion.
  • FIG. 9 illustrates a disposable fluid circuit kit which may support various embodiments of the invention.
  • FIG. 10 illustrates a set up for priming a blood treatment process, which components of the invention may be used to support.
  • FIG. 11 illustrates a portion of a blood treatment machine that allows a pump used as part of the blood treatment to also be used to control the filtering of fluid to provide a batch of infusible replacement fluid.
  • FIG. 12 illustrates replacement fluid container tubing set.
  • FIG. 13 illustrates a replacement fluid preparation apparatus.
  • FIGS. 14 , 15 , and 16 illustrate portions of the replacement fluid preparation apparatus of FIG. 13 .
  • a filter 160 filters fluid from a source of fluid 150 to generate a batch of sterile replacement fluid 130 .
  • the filter 160 may be, and preferably is, a microporous filter that blocks all materials except dissolved electrolytes and water.
  • the result of the filtration process is to sterilize the raw fluid from the source of fluid 150 .
  • the source of fluid 150 may be a container of sterile or non-sterile replacement fluid, one or more containers of constituents which, when combined, form a proper replacement fluid. Any of the latter may include a continuous source such as a water tap.
  • One or more conduit elements form a line 120 to convey the source fluid 150 through the filter 160 and into a batch container 147 .
  • the latter may be any type of sterile, preferably disposable container, for example, a large IV bag. It may also include a number of such containers appropriately interconnected to permit flow into and out of them in the fashion of container 147 .
  • a pump 190 such as a peristaltic pump.
  • the pressure at an outlet of the filter 160 may be sensed by a pressure sensor 162 and the pump 190 controlled by a controller 170 to insure a predefined transmembrane pressure (TMP) threshold of the filter 160 is not breached.
  • TMP transmembrane pressure
  • the TMP may be maintained at a maximum safe level to maximize throughput.
  • complexity may be avoided if the source fluid 150 is arranged such as to maintain a desired TMP at the filter 160 without the need of a pump 190 or pressure sensor 162 .
  • the source fluid 150 may be provided by a batch container elevated at a certain height to provide a desired head.
  • a control valve 165 or a speed of the pump 190 may be used to regulate the flow rate to maintain desired TMP limits.
  • a control/shutoff valve 180 may provide the controller 170 the ability to stop the flow of fluid through the filter 160 once a desired volume is reached.
  • a heater 185 may be provided to warm the sterile replacement fluid 130 to prepare it for use.
  • An insulated container 145 may be used to reduce heat loss so that heater 185 can be a relatively low power type.
  • the heater 185 may be controlled by the controller 170 to ensure the replacement fluid 130 is at a desired temperature when required to be used.
  • the heater 185 can be controlled by an independent device actuated by, for example, a pressure sensor (not shown) triggered by the flow of fluid into the batch container 147 , a timer (not shown) settable to trigger based on a predefined treatment time, or some other means.
  • a temperature regulator e.g., a temperature sensor 183 combined with logic in controller 170 ) regulates power to the heater to ensure a required temperature is maintained and not exceeded.
  • the temperature sensor 183 may be used to sense the quantity of sterile replacement fluid by the rate of detected temperature increase versus heater output.
  • the temperature sensor 183 , heater 185 , and sterile replacement fluid 130 can be modeled in any desired fashion. For example one may neglect all but the thermal mass of the RF, assume perfect heat transfer (including assuming the RF fluid to be isothermal). Then, the mass would be given by the product of the temperature change, the thermal capacitance of the fluid, and the heat output rate of the heater.
  • the controller 170 may be programmed to respond in accord with the assumption the sterile RF is exhausted. Equivalently, the controller 170 may simply respond to some predefined rate of temperature rise of the temperature sensor 183 .
  • a vibrator or ultrasonic transducer may be provided 183 to cause bubbles to coalesce and rise to a top of the container 147 . As a result, bubble-free replacement fluid may be drawn through the outlet 148 .
  • a connector 195 may be provided for connecting the source fluid to the line 120 .
  • the connector may be a luer, spike, threaded adapter, or any other suitable type.
  • the FIG. 1 embodiment allows replacement fluid to be prepared in batch for later use.
  • the rate of filtration of replacement fluid need not match the requirements of the treatment process or preparatory steps such as priming.
  • a low capacity filter may be used for the filter 160 .
  • typically only a small quantity of expensive media is required to make a small-capacity filter and as such, the cost of a low capacity filter can be much smaller than a high capacity filter.
  • FIG. 1 may be retrofitted for use with an existing treatment system.
  • the outlet 148 may provide with any required connection adapter.
  • a user interface 175 for entering data into the controller 170 may be provided as well.
  • a control algorithm for controlling the heater 185 , pump 190 , valves 165 / 180 , etc. begins with the a setting of a time for treatment 510 , for example by entering a time into the controller 170 via a user interface (UI) 175 .
  • the time can be entered manually or automatically by means of, for example, a data signal from a remote source via a switched or network circuit.
  • the time for treatment may be obtained from a treatment calendar entered into the controller 170 , which also may be obtained from a remote source.
  • first and second time intervals T1 and T2 are defined representing the interval required for filtration of RF and the interval required for heating of RF, respectively.
  • these values may be obtained from any of the above means (e.g., local manual or remote entry via UI/interface 175 ) or from data encoded on one of the consumables involved in the process.
  • the filter 160 , the RF fluid container 147 , the source fluid 150 container (s), or any other consumable may be provided with one or more bar-codes, RFID tags, or other suitable encoding device.
  • Such devices may provide values for T1 and T2, tables of values that depend upon other factors, or other data from which T1 and T2 may be derived.
  • the controller 170 waits until it is time to start the flow of raw RF fluid from source fluid 150 toward container 147 by comparing a current time (indicated by a clock internal to the controller 170 , which is not shown) to a difference between a scheduled treatment time and T1, which represents the lead time (ahead of the scheduled treatment) required for the filtering process.
  • a loop through step S 20 is exited to step S 30 when the clock reaches the treatment time minus T1.
  • the flow of source fluid 150 through the filter 160 is initiated. If the pump 190 is present, it may be started and regulated according to a specified TMP. The latter may be provided to the controller 170 manually or automatically through UI/interface 175 .
  • Automatic entry may be by way of a data store such as bar-code or RFID attached to the filter, for example which may be read when the filter 160 is installed in a chassis with a corresponding reader device (not shown).
  • the source fluid may be sterile and the filtration process provided as a guarantee against contamination, for example by accidental touching.
  • the controller waits for the required time for applying power to the heater 185 .
  • the delay and the initiation are controlled by step S 40 which is exited to step S 50 only when the treatment time minus the predefined interval T2 is reached.
  • the heater may be triggered by detecting fluid such as by means of a sensor (not shown) triggered by the presence of sterile replacement fluid 130 in the container 147 .
  • the sensor may be any of a variety of types, such as an ultrasonic sensor, capacitance sensor, mass sensor, optical sensor, etc.
  • Step S 60 exits to step S 70 when the source fluid is determined to be exhausted.
  • the latter may be detected by integrating the flow rate to measure the total volume (the rate may be determined by the pumping rate, for example, or by a flow meter (not shown)).
  • the exhaustion of the source fluid 150 may also be indicated by a quantity indicator (e.g., a level indicator) in the sterile replacement fluid container 147 or an intermediate container supplied through a drip chamber, for example.
  • the exhaustion of the source fluid 150 may be indicated by a sensor such as an ultrasonic sensor, capacitance sensor, mass sensor, optical sensor, a scale, etc.
  • a sensor such as an ultrasonic sensor, capacitance sensor, mass sensor, optical sensor, a scale, etc.
  • the line 120 may be clamped by actuating shutoff/control valve 180 .
  • the pump 190 may be deactivated at the point where the exhaustion of the source fluid 150 is detected at step S 70 .
  • the TMP of the filter may be monitored. If the TMP is determined by the controller 170 to be, at any point, below a predetermined nominal value or to have changed precipitously during filtration, the controller 170 may trigger an alarm or take some other action to insure that the resulting replacement fluid is handled appropriately. For example, a back-up filter could be added during treatment as discussed with respect to FIG. 5 . The TMP results could trigger an alarm at any point during filtration or could be assessed and reported at step S 70 , before treatment would begin.
  • the controller 170 pauses again at step S 80 to wait for the sterile fluid to be exhausted. This may be indicated by a signal from the treatment machine (e.g., received via UI/interface 175 ) or by direct measurement by a sensor, such as an ultrasonic sensor, capacitance sensor, mass sensor, optical sensor, a scale, etc. As mentioned above, the controller 170 , or the heater 185 itself, may be provided with a threshold temperature-rise rate that indicates the mass of fluid in the replacement fluid container 147 has fallen below a minimum level. The loop of step S 80 is exited to step S 90 where power to the heater 185 is terminated.
  • controller 170 may be provided, via a control interface, by a controller (not shown) internal to a treatment machine.
  • a controller not shown
  • the apparatus of FIG. 1 could be provided as an optional module for such a treatment machine rather than a retrofit module.
  • a combination blood treatment system and sterile replacement fluid device 310 has a replacement fluid preparation subsystem 305 configured substantially as the device of FIG. 1 .
  • a filter 260 filters fluid from a source of fluid 250 to generate a batch of sterile replacement fluid 230 as in the embodiment of FIG. 1 .
  • the source of fluid 150 may be a container of sterile or non-sterile replacement fluid, one or more containers of constituents which, when combined, form a proper replacement fluid and any of the latter may include a continuous source such as a water tap.
  • a line 220 conveys the source fluid 250 through the filter 260 and into a batch container 247 , which may be any type of sterile, preferably disposable container, for example, a large IV bag. It may also include a number of such containers appropriately interconnected to permit flow into and out of them in the fashion of container 247 .
  • a pump 290 may be provided and pressure at an outlet of the filter 260 may be sensed by a pressure sensor 262 .
  • the pump 290 may be controlled by a controller 270 to insure a maximum safe TMP to maximize throughput.
  • the pump 290 is not required and the source fluid 150 may be arranged such as to maintain a desired TMP at the filter 160 without the need of the pump 290 or pressure sensor 262 by elevation.
  • a control valve 265 or a speed of the pump 290 may be used to regulate the flow rate to maintain desired TMP limits.
  • a control/shutoff valve 280 may provide the controller 270 the ability to stop the flow of fluid through the filter 260 once a desired volume is reached.
  • a heater 285 may be provided to warm the sterile replacement fluid 130 to prepare it for use.
  • An insulated container 245 may be used and the heater controlled as discussed with respect to the FIG. 1 embodiment. Bubbles may be controlled, as discussed above, by means of a vibration or ultrasonic transducer 230 as discussed above with regard to the previous embodiment.
  • a connector 295 may be provided for connecting the source fluid to the line 220 .
  • the connector may be a luer, spike, threaded adapter, or any other suitable type.
  • an automatic controller 270 each may be controlled also by manual mechanisms. Other aspects of the control mechanisms for the embodiment of FIG. 3 may be provided as discussed with respect to FIGS. 1 and 2 .
  • FIG. 2 embodiment The benefits of the FIG. 2 embodiment are similar to those of the FIG. 1 embodiment in that it allows replacement fluid over a time period that is not driven by the speed of supply to the treatment process. As a result, a low capacity filter may be used for the filter 260 with the attendant benefits identified above.
  • the UI/interface 275 and controller 270 are shared in the present embodiment by the treatment machine. Thus, any information required for control of both the treatment and preparation of sterile replacement fluid 230 would not need to be communicated to a separate controller such as controller 170 .
  • controller 170 the communications among the illustrated components is provided by a channel 202 which may be wire harness, separate wires, a bus, a wireless channel or any suitable communications/power transmission device.
  • a predicted quantity of replacement fluid may be filtered and stored for use during treatment. If, however, for some reason, more is required, the treatment machine controller 270 could be configured to identify that situation and control the subsystem 305 components to provide it. Many blood treatment process employ a filter 220 to filter blood and into which replacement fluid is supplied to a patient 225 . More details on preferred embodiments of the treatment machine are discussed below.
  • the rate of flow of fluid during preparation of the batch of replacement fluid may be substantially less than the rate of consumption during treatment.
  • the amount of replacement fluid consumed is between 9 and 181. and the rate of consumption is approximately 200 ml./min.
  • the media used for sterile filtration may be any suitable media that insures the quality of the replacement fluid is as desired.
  • the end sought was preparation of sterile replacement fluid employed microfiltration to prevent the passage of pathogens.
  • the invention could be used with other types of filtration or treatment processes to produce a batch of fluid consumed by a medical treatment process, for example, dialysate for hemodialysis treatment.
  • the benefits accrue in particular when the time scale of preparation may be longer than the time scale of consumption. Moreover, the benefits are more appreciable when some sort of energy-consuming process is required, such as heating, before consumption.
  • the time scale of preparation compatible with a small inexpensive filter
  • the long time scale permits heating of the replacement fluid over a long interval.
  • the batch container may be insulated to minimize heat loss so a small heater will be adequate.
  • the preferred application for the present invention is in the context of hemofiltration because the quantity of fluid required for such treatment is relatively small.
  • the filter preferably is of a type that permits the passage of fluid, but which blocks the passage of bubbles, for example due to its media pore size and the surface tension of the fluid.
  • a preferred type of filter for some of the present embodiments has an inlet port 415 providing an inlet channel 410 communicating with an inlet chamber 440 .
  • An outlet leading port 405 provides an outlet channel 420 communicating with an outlet chamber 445 .
  • a piece of filter media 425 separates the inlet and outlet chambers 440 and 445 .
  • the fluid to be sterilized enters the inlet chamber 440 , is sterilized by passing through the filter media 425 , and exits via the outlet chamber 445 .
  • a gas relief gasket 425 allows gas accumulating in the inlet chamber 440 to be released to the ambient atmosphere.
  • the gas relief gasket 425 may be of a porous hydrophobic material such as PTFE. Air bubbles trapped in the inlet chamber 440 can coalesce in the inlet chamber 440 and exit via the air relief gasket 425 . It may be, depending on the type of gas relief gasket 425 used, that a substantial TMP will be required to eliminate air.
  • gas relief gasket 425 An alternative to the gas relief gasket 425 is a gas relief valve 426 as shown in FIG. 4B . Since the inlet chamber 440 is connected to the non-sterile side of the filtration system, there is little risk of contamination if microbes were to enter through a mechanical device such as the gas relief valve 426 . The latter is illustrated figuratively and allows only gas to escape. Other features of the embodiment of FIG.
  • FIG. 4 B are labeled with the same numerals as features of the embodiment of FIG. 4A where they serve substantially identical functions and, thus, their descriptions are not repeated here.
  • the filters of FIGS. 4A and 4B may be used for filtration of replacement fluid in the embodiment of FIG. 5 as discussed presently.
  • Replacement fluid 360 which may or may not be sterile, is supplied to a hemofiltration machine 490 .
  • a replacement fluid pump 360 pumps the replacement fluid into a balancing mechanism 330 which meters the replacement fluid before it is introduced, via a junction 485 , into the venous (return) line 480 and ultimately into the blood stream of a patient 225 .
  • Waste fluid is drawn through a waste line 470 from a filter 395 and pumped via a waste pump 365 through the fluid balancing mechanism 330 .
  • the fluid balancing mechanism 330 meters the replacement fluid to match the rate of withdrawal of waste fluid so that the patient's fluid balance is maintained during treatment.
  • the rate of withdrawal of waste fluid may be less than the rate of metering of replacement fluid by pumping waste fluid through a bypass pump called an ultrafiltration pump 339 .
  • the latter sends some of the waste fluid directly to a waste fluid sump 380 , thereby bypassing the fluid balancing mechanism 330 .
  • the fluid balancing mechanism is depicted figuratively and may operate in accord with any suitable control device. Preferably it meters replacement fluid on an equal-volume or equal-mass basis.
  • a preferred mechanism is described in U.S. patent application Ser. No. 09/513,911, filed Feb. 25, 2000, entitled: “Synchronized Volumetric Fluid Balancing Systems and Methods,” which is hereby incorporated by reference as if fully set forth in its entirety herein.
  • Various sensors and line clamps indicated figuratively at 335 , 355 , 320 , 385 , and 390 , may be provided to control flow and ensure safe operation.
  • a filter 337 is provided in the replacement fluid line 338 just upstream of the junction 485 .
  • the filter 337 may serve as a last chance safety net for ensuring that replacement fluid is sterile and/or that all bubbles are removed before flowing into the venous line 480 .
  • an air sensor 390 is often provided in hemofiltration systems, but detection of air normally triggers an alarm, automatic shutdown, and skilled intervention to restart the hemofiltration treatment. Obviously, this is undesirable so the system should, as effectively as possible, insure that air or other gas is not injected into the venous line 480 .
  • a hemofiltration machine was discussed, other types of treatment processes may be provided a last-chance filter similar to filter 337 .
  • hemodiafiltration, hemodialysis, or other treatments may require the infusion of replacement fluid and thereby benefit from a filter such as filter 337 .
  • the filter 337 is substantially as in the embodiment of FIG. 4A .
  • the filter 337 removes both air and pathogens.
  • a drip chamber may be used instead of employing a filter at the location indicated at 337 .
  • Suitable drip chambers are currently available with air vents and microfilters effective to remove pathogens, so they may be substituted for the filter 337 .
  • the filter 337 may serve as a mechanism for removing only air or other gases. In such cases, drip chambers which remove gas (either with or without a vent), could be employed at the above location in the fluid circuit.
  • the last chance filter or drip chamber (or combination device) 510 may be installed in a cartridge 520 that holds and orients blood and fluid circuits for a hemofiltration machine 540 .
  • a hemofiltration machine 540 the last chance filter or drip chamber (or combination device) 510 may be installed in a cartridge 520 that holds and orients blood and fluid circuits for a hemofiltration machine 540 .
  • fluid circuit components may be held in a cartridge 520 and clamped (as shown in FIG.
  • the cartridge 520 may have a preferred orientation which may insure a correct orientation for the last chance filter or drip chamber (or combination device) 510 if required by the particular device chosen. To insure orientation of the last chance filter or drip chamber (or combination device) 510 , the latter is preferably held by the cartridge 520 in a fixed orientation with respect to the cartridge 520 .
  • the last chance filter or drip chamber (or combination device) 520 may be accompanied by a device 660 for measuring the quality of the replacement fluid, such as conductivity or density.
  • a device 660 for measuring the quality of the replacement fluid such as conductivity or density.
  • This may provide a last-chance check that the replacement fluid is of the correct type.
  • a device 660 to test the fluid could be a wettable pair of contacts (not shown) formed in a tubing set 650 of the cartridge may be used in conjunction with a resistance measurement device to measure the ion concentration of the fluid.
  • a non-wettable sensor such as an ultrasonic conductivity cell could be used.
  • Other kinds of fluid quality sensors could be employed such as new types of specific-molecule detectors built on silicon wafers.
  • the tubing set 650 and cartridge 620 of which it is a part form a disposable component that is used for one treatment and disposed of.
  • the fluid quality sensor 660 may used alone or together with the last chance filter or drip chamber (or combination device) 510 .
  • FIGS. 6 and 7 are detailed, they are intended to show various components figuratively and do not reveal the details of the routing necessary to achieve the flow paths discussed with respect to them or as illustrated elsewhere.
  • the tubing set and cartridge assembly 610 may incorporate the batch replacement fluid container 625 as part of a sterile replaceable set 690 .
  • the filter 615 may have a tube 622 with a connector 620 for attachment to a source fluid 250 .
  • a tube 635 may connect the filter to the batch replacement fluid container 625 , which may be fitted with another tube 630 to convey fluid to the tubing set and cartridge assembly 610 .
  • the batch replacement fluid container 625 may also be fitted with additional connectors 670 and/or extensions (not shown) to permit the batch replacement fluid container to be used for priming blood, replacement fluid, and/or waste lines.
  • additional connectors 670 and/or extensions not shown
  • replacement fluid is circulated through a replacement fluid container 740 to flush air out of all the fluid circuiting (not all shown) of a blood treatment apparatus 710 .
  • the venous (return) and arterial (supply) blood lines 725 and 730 may be temporarily connected via connectors 750 to the replacement fluid container 740 and fluid circulated through the container 740 until gas bubbles are substantially purged from the relevant circuits.
  • the replacement fluid container 740 corresponds to the containers 147 ( FIG. 1 ), 247 ( FIG. 3 ), and 625 ( FIG. 9 ) in the foregoing figures and to respective containers in the application incorporated by reference immediately above.
  • the air and other gases may settle in the replacement fluid container 740 as the fluid circulates. Liberation of the gases would ordinarily be promoted by the application of heat from a heater 775 (with power source 770 ), which may be employed as discussed with regard to the embodiments of FIGS. 1-3 or in any suitable way to bring the temperature of the replacement fluid to body temperature.
  • Replacement fluid circuits including line 735 , blood circuits including lines 725 and 730 , and waste fluid circuits including line 780 may all be flushed with fluid from the container 740 .
  • Replacement fluid may be transferred from the replacement fluid line 735 or from the blood line 735 to the waste line, for example through a filter, to flush the waste portion of the circuit including the waste line 780 .
  • Replacement fluid may circulate through the blood circuit including lines 725 and 730 as indicated to flush the blood circuit, at least a portion of which may be closed as indicated by the arterial and venous lines 730 and 735 .
  • Disposable components such as the circuit sets of FIGS. 8 and 9 or the batch replacement fluid container 625 alone, or other components that may be used with the embodiments disclosed may be packaged with instructions for preparing infusible replacement fluid.
  • the source fluid 150 / 1250 or a concentrate which may be mixed to make the same may be supplied with instructions for sterile filtering the fluid as described in the instant specification.
  • Such may constitute packages of consumables or reusable components.
  • the filtering method may be performed at the treatment site.
  • non-sterile concentrate may be stored at the residence of a patient.
  • the concentrate may be diluted with distilled water in a source fluid container (e.g., 196 of FIG. 1 ) at the residence and processed as discussed in the instant application.
  • a source fluid container e.g., 196 of FIG. 1
  • a blood treatment machine may permit a pump 845 that, during treatment, conveys replacement fluid to a patient, to be used for filtering a sterile filtering a non-sterile source fluid.
  • the machine 810 has a common guide 850 that accommodates a fluid line 815 through which fluid is conveyed by the pump 845 , for example a peristaltic pump.
  • the line 815 - 825 may be guided by a first selected guide 830 in a first direction toward other components of an internal fluid circuit (not shown) as indicated at 825 .
  • fluid may be pumped by the same pump 845 through a line 815 - 820 that is allowed to pass out of the blood treatment machine 810 via a different guide 835 .
  • a replacement fluid container portion of a disposable tubing set includes a replacement fluid container 1 , a break-off female luer lock connector 4 , a y-connector, 5 , a pinch clamp 6 , a male luer 8 , a female luer 26 , a 0.22 micron pore anti pyrogen filter 11 , a non reopenable tubing clamp 13 , a non-breathing cap 14 on a female luer 9 , an in-line check valve 16 , a pinch clamp 18 , a break-off male luer cap and female luer 19 , and a female luer 21 and tubing branches 3 , 7 , 10 , 12 , 15 , 17 , and 20 .
  • the replacement fluid container 1 is delivered to a patient treatment setting as a sealed sterile container with all terminals sealed.
  • the replacement fluid container contains, as delivered, a concentrate solution sufficient to create a treatment batch of replacement fluid when water is added.
  • Concentrate may be added by means of the luer connector 21 .
  • the tubing branch 20 may be sealed and cut after the concentrate is added.
  • Water is added at the treatment site through connection to a water source via luer 19 .
  • the water is preferably metered to provide a predefined quantity.
  • the 0.22 micron filter is sufficient to protect against contamination before water is added to the replacement fluid container 1 .
  • a sample of diluted replacement fluid may be drawn through the luer 19 before treatment.
  • the check valve 16 prevents any contamination due to backflow from the sampling procedure.
  • the luer 9 is disconnected from the male luer 8 and the male luer connector connected to the blood treatment system.
  • FIG. 13 illustrates such a set up in overview fashion.
  • a pretreatment module 900 provides primary filtration from a raw water supply, for example tap water and feeds prefiltered water to a controller module 905 which provides various control functions, a pump, pressure detection and control, and permanent filtering capabilities which are not shown separately here.
  • Water is metered by the control module into a consumable disposable module 910 which may provide deionization, adsorption filtration, microporous filtering, chemical pretreatment, etc. and any other types of filtering that may require replacement of components.
  • the purified water is finally conveyed to the replacement fluid container circuit 915 discussed with reference to FIG. 12 .
  • pretreatment module 900 is shown in more detail.
  • a check valve 955 prevents backflow.
  • An air vent 953 removes air from the primary supply and a sediment filter 951 (which may be replaceable) provides substantial filtering of solids.
  • control module 905 is shown in greater detail.
  • a shutoff valve 1010 is provided for safety.
  • Pressure indicators 1015 and 1025 may be provided for monitoring the respective pressures in and out of a pump 1020 .
  • a high intensity ultraviolet (UV) lamp 1030 provides a sterilization mechanism.
  • the UV lamp 1030 is of such intensity and wavelength as to provide disintegration of chloramines.
  • the lamp is characterized by a 245 nm wavelength and an output power of 750 mJ/cm2 up to 1500 mJ/cm2 which is sufficient to remove chloramines.
  • the replaceable (disposable or remanufacturable) filter module 910 contains a first stage filter 1007 copper-zinc alloy which is used to subject the water to a reduction/oxidation process to remove ions. This removes ions through a chemical reaction.
  • An embodiment is KDF 85 media where about on pound is used for a flow rate of 150 ml./min water flow rate.
  • a activated carbon filter 1005 follows which is a well-known adsorption type filter. Next three stages of strong acid cation 1011 and strong base anion 1009 filters follow in series.
  • a sensor is a sensor
  • the pump 1020 may be shut off and an alarm sounded. This may come into play if an operator ignores the tester 1022 which may provide a visual signal or if the tester 1022 fails.
  • TP is a hydrophobic membrane air vent which allows air in an ultrafilter 1035 to be purged.
  • the ultrafilter 1035 may be a microtubular filter such as used for dialysis.
  • a 1.2 micron air vent may also be provided as shown at 1047 .
  • a controller 1090 may be connectable to the disposable filter module 910 and configured to stop the pump 1020 .
  • the trigger resistivity safety level to cut-off the pump 1020 may be 1 megaohm, but may be raised to 2 megohm to allow the use of required temperature compensated resistivity probes (an FDA & AAMI requirement) This does allow use of low cost in-line resistivity probes in the disposable filter module 910 .
  • Conductivity must be in the range 13.0 to 14.4 mS.
  • Nominal conductivity for the dialysate solution is 13.7 mS at 25 C. If conductivity does not meet this specification do not use it. Verify that the results are accurate. If conductivity is high additional water may be added to bring it within specification. If conductivity is low then the solution must be discarded.

Abstract

A method and device for blood treatments that use fluids such as dialysate and replacement fluid for renal replacement therapy. In an embodiment, fluid is passed either by pump or passively by gravity feed, through a microporous sterilization filter from a fluid source to a replacement fluid container. The latter forms a batch that may be used during treatment. The advantage of forming the batch before treatment is that the rate of filtering needn't match the rate of consumption during treatment. As a result, the sterilization filter can have a small capacity. In another embodiment, a filter is placed immediately prior to the point at which the sterile fluid is consumed by the treatment process. The latter may be used in combination with the former embodiment as a last-chance guarantee of sterility and/or that the fluid is free of air bubbles. It may also be used as the primary means of sterile-filtration.

Description

    BACKGROUND OF THE INVENTION
  • During hemofiltration, hemodialysis, hemodiafiltration, ultrafiltration, and other forms of renal replacement therapy, blood is drawn from a patient, passed through a filter, and returned to the patient. Depending on the type of treatment, fluids and electrolytes are exchanged in the filter between a dialysate and/or extracted from the blood by filtration. One effect may be a net loss of fluid and electrolytes from the patient and/or exhaustion of dialysate, with a concomitant need for its replenishment, again depending on the type of treatment. To replace fluid lost from the patient and keep the patient from dehydrating, replacement fluid may be injected into the patient at a rate that matches a rate of loss, with an adjustment for a desired net change in the patient's fluid complement. To replace exhausted dialysate, fresh dialysate is continuously circulated through the filter.
  • Conventionally, dialysate and/or replacement fluid is supplied from either of two sources: batches of fluid, typically in multiple bags, or a continuous source of water that is sterile-filtered and added to concentrated electrolytes to achieve the required dilution level. Because replacement fluid is injected directly into the patient, replacement fluid must be sterile. When either method is used to generate replacement fluid, there is a risk of contamination of the fluid. Contamination may occur, for example, at the point where bags of fluid are accessed (“spiked”) or at any connection in the fluid circuit linking the source to the patient.
  • In many instances, such therapies may require a large quantity of sterile fluid. A typical way to provide the large quantity of replacement fluid is to provide multiple bags of replacement fluid, dialysate, or infusate. The connection of these bags of fluid to an extracorporeal blood circuit, there is a risk of touch-contamination resulting in the introduction of biological contaminants into the fluids. Presently, methods of producing large volumes of dialysate from tap water are known, but each requires complex water purification and standardization equipment, since impurities and cleaning additives such as chlorine vary greatly in tap water from municipality to municipality and within a municipality over time. (See Twardowski U.S. Pat. Nos. 6,146,536 and 6,132,616.) Moreover, dialysate solution, whether prepared online or prepackaged, while of the proper concentration for use as a sterile replacement fluid, never enters the patient's body. Instead, dialysate flows past a semipermeable membrane that permits ions to be exchanged across the membrane until a balance between their concentrations in blood and their concentrations in the dialysis is achieved. This is effective to remove impurities from the blood and to add missing electrolytes to the blood. Because it does not have to be infused, dialysate is less expensive than solutions prepared as replacement fluids, which are injected directly into a patient.
  • Attempts to render dialysate sufficiently sterile for use as a replacement fluid in hemofiltration and hemodiafiltration have focused on continuous sterilization processes that require a separate dialysate filtration/purification apparatus that must be periodically purged and verified to provide sufficient constant flow of sterile replacement fluid required for hemofiltration. (See Chavallet U.S. Pat. Nos. 6,039,877 and 5,702,597.) Such devices are necessarily complicated and require separate pumping systems for the sterilization process. In addition, the rate of supply of dialysate for such systems is very high, requiring an expensive filter to be used. The same high-rate problem exists for the generation of replacement fluid for hemofiltration, and therefore also requires an expensive filter.
  • SUMMARY OF THE INVENTION
  • In the present invention, sterile replacement fluid or dialysate may be generated in batch form by sterile-filtering. According to embodiments of inventions disclosed, non-sterile fluid is passed through a filter prior to treatment to prepare a batch of replacement fluid. This process may be permitted to take any length of time because the rate of flow of non-sterile replacement fluid (or components thereof) through the filter is completely independent of the rate of consumption by the renal therapy. Because the filters used for sterile-filtering tend to be expensive, it may be desirable for such a batch process to employ a small filter for such filtration. Such a filter can have a flow capacity that is much lower than that required for real-time filtering of the replacement fluid (or components). In addition to preparation of sterile fluid from non-sterile fluid, embodiments of inventions disclosed may be used to sterilize already-sterile fluid as a precaution against touch contamination.
  • Generally replacement fluid is heated before being infused into a patient. This is often accomplished by heating the fluid as it is being infused with a heater with sufficient heating capacity. The capacity of the heater must be matched to the mass flow of the fluid and the temperature rise required. In a batch preparation process, where a batch of fluid is prepared over a substantial period before use, a small heater may heat the replacement fluid over a long period of time. Insulation may be provided to prevent heat loss. An insulating outer container for the sterile replacement fluid may be provided. For example, the container may be an insulated box with room for one or more large disposable sterile bags of the type normally used for infusible fluids.
  • The preparation of warm sterile replacement fluid may be automated by a control process that permits a user to set up the fluids and other materials well in advance of a scheduled treatment. The process would ensure that the replacement fluid is sterilized and heated to the proper temperature when the treatment is to begin.
  • The automation process may be permit the user to select how far in advance of the treatment the preparation should be performed. This may be useful, for example, where a particular source of replacement fluid has proved to release more than a usual quantity of dissolved gases upon heating. Heating the replacement fluid and permitting it to settle for a time before it is used may allow gases to come out of solution and settle at the top of the batch vessel or vessels. The automation process may be incorporated in the control functions of renal therapy machine.
  • The invention or inventions will be described in connection with certain preferred embodiments, with reference to the following illustrative figures so that it may be more fully understood. With reference to the figures, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention or inventions only, and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention or inventions. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention or inventions, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention or inventions may be embodied in practice.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a schematic illustration of a standalone/retrofit apparatus system for batch filtration of a sterile replacement fluid.
  • FIG. 2 is a flow chart illustrating an exemplary control procedure applicable to various embodiments of the invention including those of FIGS. 1 and 3.
  • FIG. 3 is a schematic illustration of a blood treatment machine with an attached subsystem for batch preparation of sterile replacement fluid.
  • FIGS. 4A and 4B are illustrations of fluid filters that may be use in various embodiments of the invention.
  • FIG. 5 illustrates an exemplary blood treatment system with a filter used to sterilize and/or degas replacement fluid during treatment.
  • FIGS. 6-8 illustrate a blood treatment machine and cartridge providing various supporting mechanical features for the embodiment of FIG. 5 and further embodiments, including one in which a quality of replacement fluid is sensed before infusion.
  • FIG. 9 illustrates a disposable fluid circuit kit which may support various embodiments of the invention.
  • FIG. 10 illustrates a set up for priming a blood treatment process, which components of the invention may be used to support.
  • FIG. 11 illustrates a portion of a blood treatment machine that allows a pump used as part of the blood treatment to also be used to control the filtering of fluid to provide a batch of infusible replacement fluid.
  • FIG. 12 illustrates replacement fluid container tubing set.
  • FIG. 13 illustrates a replacement fluid preparation apparatus.
  • FIGS. 14,15, and 16 illustrate portions of the replacement fluid preparation apparatus of FIG. 13.
  • DETAILED DESCRIPTION
  • Referring to FIG. 1, a filter 160 filters fluid from a source of fluid 150 to generate a batch of sterile replacement fluid 130. The filter 160 may be, and preferably is, a microporous filter that blocks all materials except dissolved electrolytes and water. Thus, the result of the filtration process is to sterilize the raw fluid from the source of fluid 150. The source of fluid 150 may be a container of sterile or non-sterile replacement fluid, one or more containers of constituents which, when combined, form a proper replacement fluid. Any of the latter may include a continuous source such as a water tap. One or more conduit elements form a line 120 to convey the source fluid 150 through the filter 160 and into a batch container 147.
  • The latter may be any type of sterile, preferably disposable container, for example, a large IV bag. It may also include a number of such containers appropriately interconnected to permit flow into and out of them in the fashion of container 147.
  • Included in the conveyance from source fluid 150 to sterile replacement fluid 130 may be a pump 190, such as a peristaltic pump. The pressure at an outlet of the filter 160 may be sensed by a pressure sensor 162 and the pump 190 controlled by a controller 170 to insure a predefined transmembrane pressure (TMP) threshold of the filter 160 is not breached. The TMP may be maintained at a maximum safe level to maximize throughput. Note that complexity may be avoided if the source fluid 150 is arranged such as to maintain a desired TMP at the filter 160 without the need of a pump 190 or pressure sensor 162. For example, the source fluid 150 may be provided by a batch container elevated at a certain height to provide a desired head. Note that a control valve 165 or a speed of the pump 190 may be used to regulate the flow rate to maintain desired TMP limits.
  • A control/shutoff valve 180 may provide the controller 170 the ability to stop the flow of fluid through the filter 160 once a desired volume is reached. A heater 185 may be provided to warm the sterile replacement fluid 130 to prepare it for use. An insulated container 145 may be used to reduce heat loss so that heater 185 can be a relatively low power type. The heater 185 may be controlled by the controller 170 to ensure the replacement fluid 130 is at a desired temperature when required to be used. Alternatively the heater 185 can be controlled by an independent device actuated by, for example, a pressure sensor (not shown) triggered by the flow of fluid into the batch container 147, a timer (not shown) settable to trigger based on a predefined treatment time, or some other means. Preferably, in either case, a temperature regulator (e.g., a temperature sensor 183 combined with logic in controller 170) regulates power to the heater to ensure a required temperature is maintained and not exceeded. The temperature sensor 183 may be used to sense the quantity of sterile replacement fluid by the rate of detected temperature increase versus heater output. The temperature sensor 183, heater 185, and sterile replacement fluid 130 can be modeled in any desired fashion. For example one may neglect all but the thermal mass of the RF, assume perfect heat transfer (including assuming the RF fluid to be isothermal). Then, the mass would be given by the product of the temperature change, the thermal capacitance of the fluid, and the heat output rate of the heater. More complex theoretical or empirical algorithms would be a simple matter to derive and implement. Once the mass of fluid is calculated to be below a certain level, the controller 170 may be programmed to respond in accord with the assumption the sterile RF is exhausted. Equivalently, the controller 170 may simply respond to some predefined rate of temperature rise of the temperature sensor 183.
  • When the temperature of the sterile replacement fluid 130 is raised, dissolved gas may come out of solution. This may cause bubbles to accumulate inside the replacement fluid container 247, which is undesirable because of the risk of infusing bubbles into the patient's bloodstream. To help ameliorate that problem, a vibrator or ultrasonic transducer may be provided 183 to cause bubbles to coalesce and rise to a top of the container 147. As a result, bubble-free replacement fluid may be drawn through the outlet 148.
  • A connector 195 may be provided for connecting the source fluid to the line 120. The connector may be a luer, spike, threaded adapter, or any other suitable type. Although the various controls indicated above are shown to be controlled an automatic controller 170, each may be controlled also by manual mechanisms.
  • The FIG. 1 embodiment allows replacement fluid to be prepared in batch for later use. Thus, the rate of filtration of replacement fluid need not match the requirements of the treatment process or preparatory steps such as priming. As a result, a low capacity filter may be used for the filter 160. For example, typically only a small quantity of expensive media is required to make a small-capacity filter and as such, the cost of a low capacity filter can be much smaller than a high capacity filter.
  • Also, other features found in high capacity filters, such as a large ratio of media surface to volume of the filter module are achievable only by means of folding or forming media into shapes that can be difficult to manufacture, such as tubes. Thus, savings can be achieved in simplification of the configuration of the filter as well. Relatively small filters with simple planar media held in plastic casings are available and suitable for this purpose.
  • The configuration of FIG. 1 may be retrofitted for use with an existing treatment system. For this purpose, the outlet 148 may provide with any required connection adapter. A user interface 175 for entering data into the controller 170 may be provided as well.
  • Referring now to FIG. 2, a control algorithm for controlling the heater 185, pump 190, valves 165/180, etc. begins with the a setting of a time for treatment 510, for example by entering a time into the controller 170 via a user interface (UI) 175. The time can be entered manually or automatically by means of, for example, a data signal from a remote source via a switched or network circuit. The time for treatment may be obtained from a treatment calendar entered into the controller 170, which also may be obtained from a remote source. In the present simple algorithm, first and second time intervals T1 and T2 are defined representing the interval required for filtration of RF and the interval required for heating of RF, respectively.
  • These values may be obtained from any of the above means (e.g., local manual or remote entry via UI/interface 175) or from data encoded on one of the consumables involved in the process. For example, the filter 160, the RF fluid container 147, the source fluid 150 container (s), or any other consumable may be provided with one or more bar-codes, RFID tags, or other suitable encoding device. Such devices may provide values for T1 and T2, tables of values that depend upon other factors, or other data from which T1 and T2 may be derived.
  • The controller 170 waits until it is time to start the flow of raw RF fluid from source fluid 150 toward container 147 by comparing a current time (indicated by a clock internal to the controller 170, which is not shown) to a difference between a scheduled treatment time and T1, which represents the lead time (ahead of the scheduled treatment) required for the filtering process. A loop through step S20 is exited to step S30 when the clock reaches the treatment time minus T1. At step S30, the flow of source fluid 150 through the filter 160 is initiated. If the pump 190 is present, it may be started and regulated according to a specified TMP. The latter may be provided to the controller 170 manually or automatically through UI/interface 175. Automatic entry may be by way of a data store such as bar-code or RFID attached to the filter, for example which may be read when the filter 160 is installed in a chassis with a corresponding reader device (not shown). Note, as mentioned above, the source fluid may be sterile and the filtration process provided as a guarantee against contamination, for example by accidental touching.
  • Once the flow of source fluid 150 is initiated, the controller waits for the required time for applying power to the heater 185. The delay and the initiation are controlled by step S40 which is exited to step S50 only when the treatment time minus the predefined interval T2 is reached. As mentioned above, alternatively, the heater may be triggered by detecting fluid such as by means of a sensor (not shown) triggered by the presence of sterile replacement fluid 130 in the container 147. The sensor may be any of a variety of types, such as an ultrasonic sensor, capacitance sensor, mass sensor, optical sensor, etc.
  • Once the heater is started, the controller 170 may wait for the source fluid to be exhausted at step S60. Step S60 exits to step S70 when the source fluid is determined to be exhausted. The latter may be detected by integrating the flow rate to measure the total volume (the rate may be determined by the pumping rate, for example, or by a flow meter (not shown)). The exhaustion of the source fluid 150 may also be indicated by a quantity indicator (e.g., a level indicator) in the sterile replacement fluid container 147 or an intermediate container supplied through a drip chamber, for example. Alternatively, the exhaustion of the source fluid 150, if supplied from a fixed-volume container, may be indicated by a sensor such as an ultrasonic sensor, capacitance sensor, mass sensor, optical sensor, a scale, etc. Yet another alternative is to sense gas or a precipitous rise in negative pressure (sensed by a pressure sensor which is not shown) at the pump 190 inlet. At step S70, the line 120 may be clamped by actuating shutoff/control valve 180. Additionally, if appropriate, the pump 190 may be deactivated at the point where the exhaustion of the source fluid 150 is detected at step S70.
  • According to an embodiment, as the fluid is pumped, the TMP of the filter, as indicated by pressure sensors 162, may be monitored. If the TMP is determined by the controller 170 to be, at any point, below a predetermined nominal value or to have changed precipitously during filtration, the controller 170 may trigger an alarm or take some other action to insure that the resulting replacement fluid is handled appropriately. For example, a back-up filter could be added during treatment as discussed with respect to FIG. 5. The TMP results could trigger an alarm at any point during filtration or could be assessed and reported at step S70, before treatment would begin.
  • The controller 170 pauses again at step S80 to wait for the sterile fluid to be exhausted. This may be indicated by a signal from the treatment machine (e.g., received via UI/interface 175) or by direct measurement by a sensor, such as an ultrasonic sensor, capacitance sensor, mass sensor, optical sensor, a scale, etc. As mentioned above, the controller 170, or the heater 185 itself, may be provided with a threshold temperature-rise rate that indicates the mass of fluid in the replacement fluid container 147 has fallen below a minimum level. The loop of step S80 is exited to step S90 where power to the heater 185 is terminated.
  • Note that all the functionality attributed to the controller 170 may be provided, via a control interface, by a controller (not shown) internal to a treatment machine. For example, the apparatus of FIG. 1 could be provided as an optional module for such a treatment machine rather than a retrofit module.
  • Referring now to FIG. 3, a combination blood treatment system and sterile replacement fluid device 310 has a replacement fluid preparation subsystem 305 configured substantially as the device of FIG. 1. A filter 260 filters fluid from a source of fluid 250 to generate a batch of sterile replacement fluid 230 as in the embodiment of FIG. 1. Again, the source of fluid 150 may be a container of sterile or non-sterile replacement fluid, one or more containers of constituents which, when combined, form a proper replacement fluid and any of the latter may include a continuous source such as a water tap. A line 220 conveys the source fluid 250 through the filter 260 and into a batch container 247, which may be any type of sterile, preferably disposable container, for example, a large IV bag. It may also include a number of such containers appropriately interconnected to permit flow into and out of them in the fashion of container 247.
  • Again, a pump 290 may be provided and pressure at an outlet of the filter 260 may be sensed by a pressure sensor 262. The pump 290 may be controlled by a controller 270 to insure a maximum safe TMP to maximize throughput. Again, the pump 290 is not required and the source fluid 150 may be arranged such as to maintain a desired TMP at the filter 160 without the need of the pump 290 or pressure sensor 262 by elevation. A control valve 265 or a speed of the pump 290 may be used to regulate the flow rate to maintain desired TMP limits.
  • A control/shutoff valve 280 may provide the controller 270 the ability to stop the flow of fluid through the filter 260 once a desired volume is reached. A heater 285 may be provided to warm the sterile replacement fluid 130 to prepare it for use. An insulated container 245 may be used and the heater controlled as discussed with respect to the FIG. 1 embodiment. Bubbles may be controlled, as discussed above, by means of a vibration or ultrasonic transducer 230 as discussed above with regard to the previous embodiment.
  • A connector 295 may be provided for connecting the source fluid to the line 220. The connector may be a luer, spike, threaded adapter, or any other suitable type. Although the various controls indicated above are shown to be controlled an automatic controller 270, each may be controlled also by manual mechanisms. Other aspects of the control mechanisms for the embodiment of FIG. 3 may be provided as discussed with respect to FIGS. 1 and 2.
  • The benefits of the FIG. 2 embodiment are similar to those of the FIG. 1 embodiment in that it allows replacement fluid over a time period that is not driven by the speed of supply to the treatment process. As a result, a low capacity filter may be used for the filter 260 with the attendant benefits identified above. Note that the UI/interface 275 and controller 270 are shared in the present embodiment by the treatment machine. Thus, any information required for control of both the treatment and preparation of sterile replacement fluid 230 would not need to be communicated to a separate controller such as controller 170. Note also that the communications among the illustrated components is provided by a channel 202 which may be wire harness, separate wires, a bus, a wireless channel or any suitable communications/power transmission device.
  • In the embodiment of FIG. 3, a predicted quantity of replacement fluid may be filtered and stored for use during treatment. If, however, for some reason, more is required, the treatment machine controller 270 could be configured to identify that situation and control the subsystem 305 components to provide it. Many blood treatment process employ a filter 220 to filter blood and into which replacement fluid is supplied to a patient 225. More details on preferred embodiments of the treatment machine are discussed below.
  • In either of the above embodiments, the rate of flow of fluid during preparation of the batch of replacement fluid may be substantially less than the rate of consumption during treatment. In an exemplary embodiment of an application for hemofiltration, the amount of replacement fluid consumed is between 9 and 181. and the rate of consumption is approximately 200 ml./min. Also, the media used for sterile filtration may be any suitable media that insures the quality of the replacement fluid is as desired. In the embodiments discussed above, it was assumed that the end sought was preparation of sterile replacement fluid employed microfiltration to prevent the passage of pathogens. However, the invention could be used with other types of filtration or treatment processes to produce a batch of fluid consumed by a medical treatment process, for example, dialysate for hemodialysis treatment. The benefits accrue in particular when the time scale of preparation may be longer than the time scale of consumption. Moreover, the benefits are more appreciable when some sort of energy-consuming process is required, such as heating, before consumption.
  • Here, not only is the time scale of preparation compatible with a small inexpensive filter, but the long time scale permits heating of the replacement fluid over a long interval. To support this benefit, the batch container may be insulated to minimize heat loss so a small heater will be adequate. Also, the preferred application for the present invention is in the context of hemofiltration because the quantity of fluid required for such treatment is relatively small.
  • Note that other motivations for filtering the fluid, in addition to or as an alternative to sterilization of a non-sterile fluid, is (1) removal of air bubbles and/or (2) as a safety net for ensuring against accidental contamination. If bubble removal is the only concern, a drip chamber may be used instead of a filter. For removing bubbles, the filter preferably is of a type that permits the passage of fluid, but which blocks the passage of bubbles, for example due to its media pore size and the surface tension of the fluid.
  • Referring now to FIG. 4A, a preferred type of filter for some of the present embodiments has an inlet port 415 providing an inlet channel 410 communicating with an inlet chamber 440. An outlet leading port 405 provides an outlet channel 420 communicating with an outlet chamber 445. A piece of filter media 425 separates the inlet and outlet chambers 440 and 445. The fluid to be sterilized enters the inlet chamber 440, is sterilized by passing through the filter media 425, and exits via the outlet chamber 445. A gas relief gasket 425 allows gas accumulating in the inlet chamber 440 to be released to the ambient atmosphere.
  • Internal supports and structural details are not shown in the illustration for clarity, but a practical embodiment of the filter of FIG. 4 may have ribs for strength and internal supports for the media 425 and gasket 425 so that the filter 400 may be capable of tolerating a substantial TMP.
  • The gas relief gasket 425 may be of a porous hydrophobic material such as PTFE. Air bubbles trapped in the inlet chamber 440 can coalesce in the inlet chamber 440 and exit via the air relief gasket 425. It may be, depending on the type of gas relief gasket 425 used, that a substantial TMP will be required to eliminate air.
  • An alternative to the gas relief gasket 425 is a gas relief valve 426 as shown in FIG. 4B. Since the inlet chamber 440 is connected to the non-sterile side of the filtration system, there is little risk of contamination if microbes were to enter through a mechanical device such as the gas relief valve 426. The latter is illustrated figuratively and allows only gas to escape. Other features of the embodiment of FIG.
  • 4B are labeled with the same numerals as features of the embodiment of FIG. 4A where they serve substantially identical functions and, thus, their descriptions are not repeated here.
  • Referring now to FIG. 5, the filters of FIGS. 4A and 4B may be used for filtration of replacement fluid in the embodiment of FIG. 5 as discussed presently.
  • Replacement fluid 360, which may or may not be sterile, is supplied to a hemofiltration machine 490. A replacement fluid pump 360 pumps the replacement fluid into a balancing mechanism 330 which meters the replacement fluid before it is introduced, via a junction 485, into the venous (return) line 480 and ultimately into the blood stream of a patient 225. Waste fluid is drawn through a waste line 470 from a filter 395 and pumped via a waste pump 365 through the fluid balancing mechanism 330. The fluid balancing mechanism 330 meters the replacement fluid to match the rate of withdrawal of waste fluid so that the patient's fluid balance is maintained during treatment. Actually, the rate of withdrawal of waste fluid may be less than the rate of metering of replacement fluid by pumping waste fluid through a bypass pump called an ultrafiltration pump 339. The latter sends some of the waste fluid directly to a waste fluid sump 380, thereby bypassing the fluid balancing mechanism 330. The fluid balancing mechanism is depicted figuratively and may operate in accord with any suitable control device. Preferably it meters replacement fluid on an equal-volume or equal-mass basis. A preferred mechanism is described in U.S. patent application Ser. No. 09/513,911, filed Feb. 25, 2000, entitled: “Synchronized Volumetric Fluid Balancing Systems and Methods,” which is hereby incorporated by reference as if fully set forth in its entirety herein. Various sensors and line clamps, indicated figuratively at 335,355, 320,385, and 390, may be provided to control flow and ensure safe operation.
  • A filter 337, is provided in the replacement fluid line 338 just upstream of the junction 485. The filter 337 may serve as a last chance safety net for ensuring that replacement fluid is sterile and/or that all bubbles are removed before flowing into the venous line 480. To ensure that air is not infused into the patient's body, an air sensor 390 is often provided in hemofiltration systems, but detection of air normally triggers an alarm, automatic shutdown, and skilled intervention to restart the hemofiltration treatment. Obviously, this is undesirable so the system should, as effectively as possible, insure that air or other gas is not injected into the venous line 480.
  • Although in the embodiment of FIG. 5, a hemofiltration machine was discussed, other types of treatment processes may be provided a last-chance filter similar to filter 337. For example, hemodiafiltration, hemodialysis, or other treatments may require the infusion of replacement fluid and thereby benefit from a filter such as filter 337. Preferably, the filter 337 is substantially as in the embodiment of FIG. 4A. Thus, the filter 337 removes both air and pathogens.
  • Instead of employing a filter at the location indicated at 337, a drip chamber may be used. Suitable drip chambers are currently available with air vents and microfilters effective to remove pathogens, so they may be substituted for the filter 337. Also, in some cases, it may be that there is very little risk that the replacement fluid is contaminated with pathogens, the filter 337 may serve as a mechanism for removing only air or other gases. In such cases, drip chambers which remove gas (either with or without a vent), could be employed at the above location in the fluid circuit.
  • Referring now to FIGS. 6,7, and 8 the last chance filter or drip chamber (or combination device) 510 may be installed in a cartridge 520 that holds and orients blood and fluid circuits for a hemofiltration machine 540. In the embodiment shown, which is described substantially in U.S. patent application Ser. No. 09/513, 773 filed Feb. 25, 2000 and entitled: “Fluid Processing Systems and Methods Using Extracorporeal Fluid Flow Panels Oriented Within A Cartridge,” hereby incorporated by reference in its entirety as if fully set forth herein, fluid circuit components may be held in a cartridge 520 and clamped (as shown in FIG. 8 with the machine closing as illustrated by the arrow 665) within a receiving gap 530 in a blood treatment machine such as hemofiltration machine 540. The cartridge 520 may have a preferred orientation which may insure a correct orientation for the last chance filter or drip chamber (or combination device) 510 if required by the particular device chosen. To insure orientation of the last chance filter or drip chamber (or combination device) 510, the latter is preferably held by the cartridge 520 in a fixed orientation with respect to the cartridge 520.
  • In an alternative embodiment, the last chance filter or drip chamber (or combination device) 520 may be accompanied by a device 660 for measuring the quality of the replacement fluid, such as conductivity or density. This may provide a last-chance check that the replacement fluid is of the correct type. For example, where such fluids are derived from mixtures, if the proportion is not exactly what is required, infusion could be harmful to the patient 225. An example of a device 660 to test the fluid could be a wettable pair of contacts (not shown) formed in a tubing set 650 of the cartridge may be used in conjunction with a resistance measurement device to measure the ion concentration of the fluid. Alternatively, a non-wettable sensor, such as an ultrasonic conductivity cell could be used. Other kinds of fluid quality sensors could be employed such as new types of specific-molecule detectors built on silicon wafers.
  • Preferably, the tubing set 650 and cartridge 620 of which it is a part form a disposable component that is used for one treatment and disposed of. Note that the fluid quality sensor 660 may used alone or together with the last chance filter or drip chamber (or combination device) 510. Note, although FIGS. 6 and 7 are detailed, they are intended to show various components figuratively and do not reveal the details of the routing necessary to achieve the flow paths discussed with respect to them or as illustrated elsewhere.
  • Referring now also to FIG. 9, the tubing set and cartridge assembly 610, discussed previously, may incorporate the batch replacement fluid container 625 as part of a sterile replaceable set 690. The filter 615 may have a tube 622 with a connector 620 for attachment to a source fluid 250. A tube 635 may connect the filter to the batch replacement fluid container 625, which may be fitted with another tube 630 to convey fluid to the tubing set and cartridge assembly 610. Referring now also to FIG. 10, the batch replacement fluid container 625 may also be fitted with additional connectors 670 and/or extensions (not shown) to permit the batch replacement fluid container to be used for priming blood, replacement fluid, and/or waste lines. For example, as discussed in U.S. patent application Ser. No. 09/905,246, filed Jul. 12, 2001, entitled: “Devices and Methods For Sterile Filtering of Dialysate,” which is hereby incorporated by reference as if fully set forth in its entirety herein, replacement fluid is circulated through a replacement fluid container 740 to flush air out of all the fluid circuiting (not all shown) of a blood treatment apparatus 710. As described in detail in the'246 application incorporated by reference above, the venous (return) and arterial (supply) blood lines 725 and 730 may be temporarily connected via connectors 750 to the replacement fluid container 740 and fluid circulated through the container 740 until gas bubbles are substantially purged from the relevant circuits.
  • Note, the replacement fluid container 740 corresponds to the containers 147 (FIG. 1), 247 (FIG. 3), and 625 (FIG. 9) in the foregoing figures and to respective containers in the application incorporated by reference immediately above. The air and other gases may settle in the replacement fluid container 740 as the fluid circulates. Liberation of the gases would ordinarily be promoted by the application of heat from a heater 775 (with power source 770), which may be employed as discussed with regard to the embodiments of FIGS. 1-3 or in any suitable way to bring the temperature of the replacement fluid to body temperature. Replacement fluid circuits including line 735, blood circuits including lines 725 and 730, and waste fluid circuits including line 780 may all be flushed with fluid from the container 740. The details of the blood treatment apparatus and its internal plumbing can vary. Replacement fluid may be transferred from the replacement fluid line 735 or from the blood line 735 to the waste line, for example through a filter, to flush the waste portion of the circuit including the waste line 780. Replacement fluid may circulate through the blood circuit including lines 725 and 730 as indicated to flush the blood circuit, at least a portion of which may be closed as indicated by the arterial and venous lines 730 and 735.
  • Disposable components, such as the circuit sets of FIGS. 8 and 9 or the batch replacement fluid container 625 alone, or other components that may be used with the embodiments disclosed may be packaged with instructions for preparing infusible replacement fluid. For example, the source fluid 150/1250 or a concentrate which may be mixed to make the same (FIGS. 1 and 3) may be supplied with instructions for sterile filtering the fluid as described in the instant specification. Such may constitute packages of consumables or reusable components.
  • Note that benefits of the filtering method and apparatus discussed above may best be achieved by performing the filtration just prior to treatment, although this is not required. The filtering method may be performed at the treatment site. For example, non-sterile concentrate may be stored at the residence of a patient.
  • The concentrate may be diluted with distilled water in a source fluid container (e.g., 196 of FIG. 1) at the residence and processed as discussed in the instant application.
  • Because the infusible fluid is generated at the treatment site, the need for regulatory-cleared fluids, such as might be obtained from a manufacturer, is not avoided. Cost savings and storage-space economies can thus be realized by the patient. This is particularly important in view of the fact that renal replacement therapies are often administered many times per week and storage and cost of consumables can present a serious problem in a residence or any other facility.
  • Referring now to FIG. 11, a blood treatment machine, a portion of which is illustrated figuratively at 810, may permit a pump 845 that, during treatment, conveys replacement fluid to a patient, to be used for filtering a sterile filtering a non-sterile source fluid. Here, the machine 810 has a common guide 850 that accommodates a fluid line 815 through which fluid is conveyed by the pump 845, for example a peristaltic pump. During treatment, the line 815-825 may be guided by a first selected guide 830 in a first direction toward other components of an internal fluid circuit (not shown) as indicated at 825. During sterile-filtering, fluid may be pumped by the same pump 845 through a line 815-820 that is allowed to pass out of the blood treatment machine 810 via a different guide 835. This allows the line 815-820 to be fed to an external connection to the sterile fluid container (not shown) as indicated at 820.
  • Referring now to FIG. 12, another embodiment of a replacement fluid container portion of a disposable tubing set includes a replacement fluid container 1, a break-off female luer lock connector 4, a y-connector, 5, a pinch clamp 6, a male luer 8, a female luer 26, a 0.22 micron pore anti pyrogen filter 11, a non reopenable tubing clamp 13, a non-breathing cap 14 on a female luer 9, an in-line check valve 16, a pinch clamp 18, a break-off male luer cap and female luer 19, and a female luer 21 and tubing branches 3,7, 10,12, 15,17, and 20. The replacement fluid container 1 is delivered to a patient treatment setting as a sealed sterile container with all terminals sealed. The replacement fluid container contains, as delivered, a concentrate solution sufficient to create a treatment batch of replacement fluid when water is added.
  • Concentrate may be added by means of the luer connector 21. In the deliverable to the treatment site, the tubing branch 20 may be sealed and cut after the concentrate is added. Water is added at the treatment site through connection to a water source via luer 19. The water is preferably metered to provide a predefined quantity. The 0.22 micron filter is sufficient to protect against contamination before water is added to the replacement fluid container 1. A sample of diluted replacement fluid may be drawn through the luer 19 before treatment. The check valve 16 prevents any contamination due to backflow from the sampling procedure. After water is added to the replacement fluid container 1, the luer 9 is disconnected from the male luer 8 and the male luer connector connected to the blood treatment system.
  • To supply suitable water that is substantially free of unwanted dissolved and undissolved materials, a combination of permanent and replaceable components may be provided at the treatment site. FIG. 13 illustrates such a set up in overview fashion. A pretreatment module 900 provides primary filtration from a raw water supply, for example tap water and feeds prefiltered water to a controller module 905 which provides various control functions, a pump, pressure detection and control, and permanent filtering capabilities which are not shown separately here. Water is metered by the control module into a consumable disposable module 910 which may provide deionization, adsorption filtration, microporous filtering, chemical pretreatment, etc. and any other types of filtering that may require replacement of components. The purified water is finally conveyed to the replacement fluid container circuit 915 discussed with reference to FIG. 12.
  • Referring to FIG. 14, pretreatment module 900 is shown in more detail. A check valve 955 prevents backflow. An air vent 953 removes air from the primary supply and a sediment filter 951 (which may be replaceable) provides substantial filtering of solids.
  • Referring to FIG. 15, the control module 905 is shown in greater detail. A shutoff valve 1010 is provided for safety. Pressure indicators 1015 and 1025 may be provided for monitoring the respective pressures in and out of a pump 1020.
  • Feedback regulation may be provided to ensure that consistent metering is provided if the pump is relied upon for measuring the total quantity of water supplied to the replacement fluid container 1. A high intensity ultraviolet (UV) lamp 1030 provides a sterilization mechanism. Preferably, the UV lamp 1030 is of such intensity and wavelength as to provide disintegration of chloramines. In a preferred embodiment, the lamp is characterized by a 245 nm wavelength and an output power of 750 mJ/cm2 up to 1500 mJ/cm2 which is sufficient to remove chloramines.
  • Referring to FIG. 16, the replaceable (disposable or remanufacturable) filter module 910 contains a first stage filter 1007 copper-zinc alloy which is used to subject the water to a reduction/oxidation process to remove ions. This removes ions through a chemical reaction. An embodiment is KDF 85 media where about on pound is used for a flow rate of 150 ml./min water flow rate. A activated carbon filter 1005 follows which is a well-known adsorption type filter. Next three stages of strong acid cation 1011 and strong base anion 1009 filters follow in series. A sensor
  • 1022 detects ion concentration by contact testing of the conductivity of the water. A signal is generated to indicate that this is the last allowed batch before replacement of the replaceable module 910. A mixed bed deionoization filter 1030 is provided next and a safeguard conductivity test is provided with an audible alarm at 1025 as a back up safety measure. If the conductivity it detects is above a certain level, the pump 1020 may be shut off and an alarm sounded. This may come into play if an operator ignores the tester 1022 which may provide a visual signal or if the tester 1022 fails.
  • TP is a hydrophobic membrane air vent which allows air in an ultrafilter 1035 to be purged. The ultrafilter 1035 may be a microtubular filter such as used for dialysis. A 1.2 micron air vent may also be provided as shown at 1047.
  • Note the final conductivity sensor/alarm 1025 may control the pump, as noted. A controller 1090 may be connectable to the disposable filter module 910 and configured to stop the pump 1020. The trigger resistivity safety level to cut-off the pump 1020 may be 1 megaohm, but may be raised to 2 megohm to allow the use of required temperature compensated resistivity probes (an FDA & AAMI requirement) This does allow use of low cost in-line resistivity probes in the disposable filter module 910.
  • The following is a procedure for using the above devices discussed with reference to FIGS. 12-16.
  • 1. Remove the dialysate concentrate tubing set 915 and remove the cap 14 from the tubing line 7 that contains the filter 11. (The 0.22 micron filter 11 provides additional protection from inadvertent contamination.)
  • 2. Connect the water source to the concentrate bag luer connection 9.
  • 3. Break the frangible luer connector 4 which connector is configured
  • to form a permanent seal on the side facing the Y-junction 5 when disconnected.
  • 4. Add 3 liters of water into the concentrate bag using the purification plant through tubing branch 7 through luer connector 9.
  • 5. Write on the bag label the date and time water was first added to the concentrate bag, to assist in ensuring that it is used within 24 hours.
  • 6. Shake the replacement fluid container 1 well to mix.
  • 7. Confirm solution conductivity prior to use. Remove the break-off cap 1 and draw sample from this branch 16. After removing the sample, clamp the line using the pinch clamp 18 provided.
  • 8. (The following is normative according to a preferred embodiment and not limiting of the invention) Conductivity must be in the range 13.0 to 14.4 mS.
  • Nominal conductivity for the dialysate solution is 13.7 mS at 25 C. If conductivity does not meet this specification do not use it. Verify that the results are accurate. If conductivity is high additional water may be added to bring it within specification. If conductivity is low then the solution must be discarded.
  • 9. Using the non re-opening clamp 13 provided, clamp the line that is connected to the water purification plant.
  • 10. Using the clamp 6 is next clamped on the line that is connected to the dialysate bagl.
  • 11. Disconnect the water source at the luer connection 26
  • 12. Connect the bag of dialysate solution to the dialysis circuit at the connection 8. This leaves the filter 11 and permanent clamp 13 in place to protect the water supply source.
  • 13. Unclamp the line going to the dialysate bag (red clamp), and initiate treatment after verifying that dialysate will be used within 24 hours from when water was added.
  • Although the foregoing invention has, for the purposes of clarity and understanding, been described in some detail by way of illustration and example, it will be obvious that certain changes and modifications may be practiced that will still fall within the scope of the appended claims. For example, the devices and methods of each embodiment can be combined with or used in any of the other embodiments.

Claims (19)

1. (canceled)
2. A system for preparing a batch of treatment fluid, comprising:
a controller with a user interface connected with a treatment machine that consumes a predefined treatment fluid;
a fluid purification element including a pump, a control valve, at least one sterile filter, a pressure sensor;
a batch element including batch heating element and a batch container, the batch container being connected to receive fluid through a connecting line from the fluid purification element, the pump and control valve being connected to control flow through the connecting line;
the controller being connected to control functions of the treatment machine, the fluid purification element pump and control valve, and the heating element;
a drain line connected to the batch container the drain line having a drain pump, the drain line having a conductivity sensor;
the controller being connected to control functions of the treatment machine, the fluid purification element pump and control valve, the drain pump, and the heating element;
the controller being further connected to receive pressure signals from the pressure sensor and the conductivity sensor;
the controller being configured to control the control valve and pump to draw fluid through the connecting line and through the filter into the batch container thereby to dilute concentrate in the batch container and to drain fluid from the batch container while sampling a conductivity signal from the conductivity sensor at least once thereafter, the conductivity signal indicating a conductivity of a diluted contents of the batch;
the controller being configured to output a signal responsive to difference between the conductivity signal and a predefined signal;
the controller being configured to operate the treatment machine responsively to a result of said output signal.
3. The system of claim 2, wherein the controller closes the control valve responsively to a reading from the pressure sensor.
4. The system of claim 2, wherein the batch container is at least partly enclosed in an insulated container.
5. The system of claim 4, wherein the insulated container includes a thermostat.
6. The system of claim 2, wherein the controller maintains a temperature of the batch container.
7. The system of claim 2, wherein the controller tests the integrity of the filter by comparing the pressure signals to predefined range and prevents use of the treatment system responsively to said pressure signals.
8. A system for preparing a batch of treatment fluid, comprising:
a controller with a user interface connected with a treatment machine that consumes a predefined treatment fluid;
a fluid purification element including a pump, a control valve, at least one filter adapted for removing ionic species and biological contaminants, a pressure sensor;
a batch element including batch heating element and a batch container, the batch container being connected to receive fluid through a connecting line from the fluid purification element, the pump and control valve being connected to control flow through the connecting line;
the controller being connected to control functions of the treatment machine, the fluid purification element pump and control valve, and the heating element;
a drain line connected to the batch container the drain line having a drain pump, the drain line having a conductivity sensor;
the controller being connected to control functions of the treatment machine, the fluid purification element pump and control valve, the drain pump, and the heating element;
the controller being further connected to receive pressure signals from the pressure sensor and the conductivity sensor;
the controller being configured to control the control valve and pump to draw fluid through the connecting line and through the filter into the batch container thereby to dilute concentrate in the batch container and to drain fluid from the batch container while sampling a conductivity signal from the conductivity sensor at least once thereafter, the conductivity signal indicating a conductivity of a diluted contents of the batch;
the controller being configured to output a signal responsive to difference between the conductivity signal and a predefined signal;
the controller being configured to operate the treatment machine responsively to a result of said output signal.
9. The system of claim 8, wherein the controller closes the control valve responsively to a reading from the pressure sensor.
10. The system of claim 8, wherein the batch container is at least partly enclosed in an insulated container.
11. The system of claim 10, wherein the insulated container includes a thermostat.
12. The system of claim 8, wherein the controller maintains a temperature of the batch container.
13. The system of claim 8, wherein the controller tests the integrity of the filter by comparing the pressure signals to predefined range and prevents use of the treatment system responsively to said pressure signals.
14. A system for preparing a batch of treatment fluid, comprising:
a controller with a user interface connected with a treatment machine that employs a predefined treatment fluid;
a fluid purification element including a pump, a control valve, at least one sterile filter, a pressure sensor;
a batch element including batch heating element and a batch container, the batch container being connected to receive fluid through a connecting line from the fluid purification element, the pump and control valve being connected to control flow through the connecting line;
the controller being connected to control functions of the treatment machine, the fluid purification element pump and control valve, and the heating element;
a drain line connected to the batch container the drain line, the drain line with a conductivity sensor;
the controller being connected to control functions of the treatment machine, the fluid purification element pump and control valve, and the heating element;
the controller being further connected to receive pressure signals from the pressure sensor and the conductivity sensor;
the controller being configured to control the control valve and pump to draw fluid through the connecting line and through the filter into the batch container thereby to dilute concentrate in the batch container and to drain a sample of fluid from the batch container while sampling a conductivity signal from the conductivity sensor at least once thereafter, the conductivity signal indicating a conductivity of a diluted contents of the batch;
the controller being configured to output a signal responsive to difference between the conductivity signal and a predefined signal;
the controller being configured to operate the treatment machine responsively to a result of said output signal.
15. The system of claim 14, wherein the controller closes the control valve responsively to a reading from the pressure sensor.
16. The system of claim 14, wherein the batch container is at least partly enclosed in an insulated container.
17. The system of claim 16, wherein the insulated container includes a thermostat.
18. The system of claim 14, wherein the controller maintains a temperature of the batch container.
19. The system of claim 14, wherein the controller tests the integrity of the filter by comparing the pressure signals to predefined range and prevents use of the treatment system responsively to said pressure signals.
US14/269,076 2003-01-07 2014-05-02 Batch filtration system for preparation of sterile fluid for renal replacement therapy Abandoned US20140238909A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/269,076 US20140238909A1 (en) 2003-01-07 2014-05-02 Batch filtration system for preparation of sterile fluid for renal replacement therapy

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US43856703P 2003-01-07 2003-01-07
PCT/US2004/000476 WO2004062710A2 (en) 2003-01-07 2004-01-07 Batch filtration system for preparation of sterile replacement fluid for renal therapy
US11/160,764 US7544300B2 (en) 2003-01-07 2005-07-07 Batch filtration system for preparation of sterile fluid for renal replacement therapy
US12/434,246 US7749393B2 (en) 2003-01-07 2009-05-01 Batch filtration system for preparation of sterile fluid for renal replacement therapy
US12/786,255 US7976711B2 (en) 2003-01-07 2010-05-24 Batch filtration system for preparation of sterile fluid for renal replacement therapy
US13/159,045 US8202420B2 (en) 2003-01-07 2011-06-13 Batch filtration system for preparation of sterile fluid for renal replacement therapy
US13/526,145 US8460558B2 (en) 2003-01-07 2012-06-18 Batch filtration system for preparation of sterile fluid for renal replacement therapy
US13/909,990 US20130264250A1 (en) 2003-01-07 2013-06-04 Batch filtration system for preparation of sterile fluid for renal replacement therapy
US14/269,076 US20140238909A1 (en) 2003-01-07 2014-05-02 Batch filtration system for preparation of sterile fluid for renal replacement therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/909,990 Continuation US20130264250A1 (en) 2003-01-07 2013-06-04 Batch filtration system for preparation of sterile fluid for renal replacement therapy

Publications (1)

Publication Number Publication Date
US20140238909A1 true US20140238909A1 (en) 2014-08-28

Family

ID=32736511

Family Applications (11)

Application Number Title Priority Date Filing Date
US11/160,764 Expired - Lifetime US7544300B2 (en) 2003-01-07 2005-07-07 Batch filtration system for preparation of sterile fluid for renal replacement therapy
US12/434,246 Expired - Lifetime US7749393B2 (en) 2003-01-07 2009-05-01 Batch filtration system for preparation of sterile fluid for renal replacement therapy
US12/786,255 Expired - Lifetime US7976711B2 (en) 2003-01-07 2010-05-24 Batch filtration system for preparation of sterile fluid for renal replacement therapy
US13/083,915 Active 2025-11-29 US8679348B2 (en) 2003-01-07 2011-04-11 Filtration system for preparation of fluids for medical applications
US13/159,045 Expired - Lifetime US8202420B2 (en) 2003-01-07 2011-06-13 Batch filtration system for preparation of sterile fluid for renal replacement therapy
US13/526,145 Expired - Lifetime US8460558B2 (en) 2003-01-07 2012-06-18 Batch filtration system for preparation of sterile fluid for renal replacement therapy
US13/603,505 Active US8545428B2 (en) 2003-01-07 2012-09-05 Filtration system for preparation of fluids for medical applications
US13/909,990 Abandoned US20130264250A1 (en) 2003-01-07 2013-06-04 Batch filtration system for preparation of sterile fluid for renal replacement therapy
US13/968,430 Active 2025-11-04 US9388059B2 (en) 2003-01-07 2013-08-16 Filtration system for preparation of fluids for medical applications
US14/269,076 Abandoned US20140238909A1 (en) 2003-01-07 2014-05-02 Batch filtration system for preparation of sterile fluid for renal replacement therapy
US15/615,655 Active 2026-03-11 US10420871B2 (en) 2003-01-07 2017-06-06 Filtration system for preparation of fluids for medical applications

Family Applications Before (9)

Application Number Title Priority Date Filing Date
US11/160,764 Expired - Lifetime US7544300B2 (en) 2003-01-07 2005-07-07 Batch filtration system for preparation of sterile fluid for renal replacement therapy
US12/434,246 Expired - Lifetime US7749393B2 (en) 2003-01-07 2009-05-01 Batch filtration system for preparation of sterile fluid for renal replacement therapy
US12/786,255 Expired - Lifetime US7976711B2 (en) 2003-01-07 2010-05-24 Batch filtration system for preparation of sterile fluid for renal replacement therapy
US13/083,915 Active 2025-11-29 US8679348B2 (en) 2003-01-07 2011-04-11 Filtration system for preparation of fluids for medical applications
US13/159,045 Expired - Lifetime US8202420B2 (en) 2003-01-07 2011-06-13 Batch filtration system for preparation of sterile fluid for renal replacement therapy
US13/526,145 Expired - Lifetime US8460558B2 (en) 2003-01-07 2012-06-18 Batch filtration system for preparation of sterile fluid for renal replacement therapy
US13/603,505 Active US8545428B2 (en) 2003-01-07 2012-09-05 Filtration system for preparation of fluids for medical applications
US13/909,990 Abandoned US20130264250A1 (en) 2003-01-07 2013-06-04 Batch filtration system for preparation of sterile fluid for renal replacement therapy
US13/968,430 Active 2025-11-04 US9388059B2 (en) 2003-01-07 2013-08-16 Filtration system for preparation of fluids for medical applications

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/615,655 Active 2026-03-11 US10420871B2 (en) 2003-01-07 2017-06-06 Filtration system for preparation of fluids for medical applications

Country Status (5)

Country Link
US (11) US7544300B2 (en)
EP (1) EP1592494B1 (en)
AT (1) ATE434454T1 (en)
DE (1) DE602004021672D1 (en)
WO (1) WO2004062710A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100621A1 (en) * 2015-12-11 2017-06-15 Nxstage Medical, Inc. Fluid line connector devices methods and systems
US10406269B2 (en) 2015-12-29 2019-09-10 Fresenius Medical Care Holdings, Inc. Electrical sensor for fluids
US10617809B2 (en) 2015-12-29 2020-04-14 Fresenius Medical Care Holdings, Inc. Electrical sensor for fluids

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2357016B1 (en) 2002-01-31 2016-04-20 Fenwal, Inc. Irreversibly closable flow control clamp
US8262639B2 (en) 2002-01-31 2012-09-11 Fenwal, Inc. Irreversible flow control clamp
AU2003237403A1 (en) 2002-06-06 2003-12-22 Nxstage Medical, Inc. Last-chance quality check and/or air/pyrogen filter for infusion systems
ATE505223T1 (en) 2002-07-19 2011-04-15 Baxter Int SYSTEM FOR PERITONEAL DIALYSIS
US9700663B2 (en) 2005-01-07 2017-07-11 Nxstage Medical, Inc. Filtration system for preparation of fluids for medical applications
US20080210606A1 (en) * 2004-01-07 2008-09-04 Jeffrey Burbank Filtration System Preparation of Fluids for Medical Applications
DE602004021672D1 (en) 2003-01-07 2009-08-06 Nxstage Medical Inc CHARGE FILTRATION SYSTEM FOR PRODUCING A STERILE SPARELIFE FLUID FOR NURSING TREATMENTS
US8029454B2 (en) 2003-11-05 2011-10-04 Baxter International Inc. High convection home hemodialysis/hemofiltration and sorbent system
JP4734343B2 (en) * 2005-01-07 2011-07-27 エヌエックスステージ・メディカル・インコーポレイテッド Purification system for solution preparation for medical applications
EP1850910A1 (en) 2005-02-07 2007-11-07 Medtronic, Inc. Ion imbalance detector
EP1883434B1 (en) * 2005-05-06 2014-01-22 Quanta Fluid Solutions Ltd Fluid processing apparatus
US20090222671A1 (en) * 2005-10-25 2009-09-03 Burbank Jeffrey H Safety features for medical devices requiring assistance and supervision
ATE477438T1 (en) * 2006-04-07 2010-08-15 Nxstage Medical Inc HOSE CLAMP FOR MEDICAL APPLICATIONS
US20090268201A1 (en) * 2006-05-01 2009-10-29 Patrick Call Integrated mold detector
DE102006060611B4 (en) * 2006-12-21 2008-11-20 Franz Ferdinand Dr.-Ing. Becker Arrangement for connecting a medical device to a water pipe
FR2915105A1 (en) 2007-04-19 2008-10-24 Gambro Lundia Ab MEDICAL FLUID TREATMENT APPARATUS AND METHOD FOR PREPARING MEDICAL FLUID TREATMENT APPARATUS.
US7957927B2 (en) 2007-07-05 2011-06-07 Baxter International Inc. Temperature compensation for pneumatic pumping system
US7736328B2 (en) 2007-07-05 2010-06-15 Baxter International Inc. Dialysis system having supply container autoconnection
US7892332B2 (en) * 2007-10-01 2011-02-22 Baxter International Inc. Dialysis systems having air traps with internal structures to enhance air removal
US8123947B2 (en) * 2007-10-22 2012-02-28 Baxter International Inc. Priming and air removal systems and methods for dialysis
DE102007056237A1 (en) * 2007-11-22 2009-05-28 Fresenius Medical Care Deutschland Gmbh Dialysis tank with heated dialysate tank and appropriate dialysis system and method
US10973968B2 (en) 2008-02-14 2021-04-13 Baxter International Inc. Control of a water device via a dialysis machine user interface
US10089443B2 (en) 2012-05-15 2018-10-02 Baxter International Inc. Home medical device systems and methods for therapy prescription and tracking, servicing and inventory
US8062513B2 (en) 2008-07-09 2011-11-22 Baxter International Inc. Dialysis system and machine having therapy prescription recall
US8057679B2 (en) 2008-07-09 2011-11-15 Baxter International Inc. Dialysis system having trending and alert generation
US9514283B2 (en) 2008-07-09 2016-12-06 Baxter International Inc. Dialysis system having inventory management including online dextrose mixing
US10265454B2 (en) 2008-07-25 2019-04-23 Baxter International Inc. Dialysis system with flow regulation device
US9399091B2 (en) 2009-09-30 2016-07-26 Medtronic, Inc. System and method to regulate ultrafiltration
US8753515B2 (en) 2009-12-05 2014-06-17 Home Dialysis Plus, Ltd. Dialysis system with ultrafiltration control
TWI442910B (en) * 2010-01-27 2014-07-01 Ta Lun Tan Intelligent automatic peritoneal dialysis apparatus
DE102010011465A1 (en) 2010-03-15 2011-09-15 Fresenius Medical Care Deutschland Gmbh System for performing a blood treatment
DE102010022201A1 (en) 2010-05-20 2011-11-24 Fresenius Medical Care Deutschland Gmbh Medical treatment arrangement
US8501009B2 (en) 2010-06-07 2013-08-06 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Fluid purification system
US9585810B2 (en) 2010-10-14 2017-03-07 Fresenius Medical Care Holdings, Inc. Systems and methods for delivery of peritoneal dialysis (PD) solutions with integrated inter-chamber diffuser
US20120199205A1 (en) 2011-02-03 2012-08-09 Fresenius Medical Care Deutschland Gmbh System for preparing a medical fluid and method for preparing a medical fluid
US8869612B2 (en) 2011-03-08 2014-10-28 Baxter International Inc. Non-invasive radio frequency liquid level and volume detection system using phase shift
EP2688602B1 (en) 2011-03-23 2019-11-06 NxStage Medical, Inc. Peritoneal dialysis systems, devices, and methods
US9456755B2 (en) 2011-04-29 2016-10-04 Medtronic, Inc. Method and device to monitor patients with kidney disease
US9848778B2 (en) 2011-04-29 2017-12-26 Medtronic, Inc. Method and device to monitor patients with kidney disease
US9192707B2 (en) 2011-04-29 2015-11-24 Medtronic, Inc. Electrolyte and pH monitoring for fluid removal processes
US9593026B2 (en) * 2011-05-06 2017-03-14 Johnson Matthey Public Limited Company Organic contaminant destruction using chlorine or mixed oxidant solution and ultraviolet light
JP6002759B2 (en) 2011-06-01 2016-10-05 フレセニウス メディカル ケア ホールディングス インコーポレーテッド Method and system for monitoring inlet temperature for centralized heat sterilization of dialyzer inlet line
CN103889481B (en) 2011-08-02 2016-03-09 美敦力公司 With the hemodialysis system of flow path with controlled compliance volume
DE112012003387T5 (en) 2011-08-15 2014-04-30 Nxstage Medical, Inc. Devices, methods and systems for detecting leaks in medical devices
US10857277B2 (en) 2011-08-16 2020-12-08 Medtronic, Inc. Modular hemodialysis system
US9707330B2 (en) 2011-08-22 2017-07-18 Medtronic, Inc. Dual flow sorbent cartridge
WO2013052680A2 (en) 2011-10-07 2013-04-11 Home Dialysis Plus, Ltd. Heat exchange fluid purification for dialysis system
US20130146541A1 (en) 2011-12-13 2013-06-13 Nxstage Medical, Inc. Fluid purification methods, devices, and systems
US9713668B2 (en) 2012-01-04 2017-07-25 Medtronic, Inc. Multi-staged filtration system for blood fluid removal
EP2641624B1 (en) * 2012-03-21 2016-03-02 Gambro Lundia AB Treatment solution delivery in an extracorporeal blood treatment apparatus
US9833606B2 (en) 2012-09-07 2017-12-05 Fenwal, Inc. Non-reopenable flow control clamp
US10905816B2 (en) 2012-12-10 2021-02-02 Medtronic, Inc. Sodium management system for hemodialysis
US11154648B2 (en) 2013-01-09 2021-10-26 Medtronic, Inc. Fluid circuits for sorbent cartridge with sensors
US11565029B2 (en) 2013-01-09 2023-01-31 Medtronic, Inc. Sorbent cartridge with electrodes
US9713666B2 (en) 2013-01-09 2017-07-25 Medtronic, Inc. Recirculating dialysate fluid circuit for blood measurement
US9707328B2 (en) 2013-01-09 2017-07-18 Medtronic, Inc. Sorbent cartridge to measure solute concentrations
GB2525353A (en) * 2013-01-24 2015-10-21 Nxstage Medical Inc Water treatment systems, devices, and methods for fluid preparation
US10543052B2 (en) 2013-02-01 2020-01-28 Medtronic, Inc. Portable dialysis cabinet
US10010663B2 (en) 2013-02-01 2018-07-03 Medtronic, Inc. Fluid circuit for delivery of renal replacement therapies
US10850016B2 (en) 2013-02-01 2020-12-01 Medtronic, Inc. Modular fluid therapy system having jumpered flow paths and systems and methods for cleaning and disinfection
US9526822B2 (en) 2013-02-01 2016-12-27 Medtronic, Inc. Sodium and buffer source cartridges for use in a modular controlled compliant flow path
US9623164B2 (en) 2013-02-01 2017-04-18 Medtronic, Inc. Systems and methods for multifunctional volumetric fluid control
US9827361B2 (en) 2013-02-02 2017-11-28 Medtronic, Inc. pH buffer measurement system for hemodialysis systems
US9144640B2 (en) 2013-02-02 2015-09-29 Medtronic, Inc. Sorbent cartridge configurations for improved dialysate regeneration
CA2836575A1 (en) * 2013-03-14 2014-09-14 Baxter International Inc. Control of a water device via a dialysis machine user interface
EP2996738B1 (en) 2013-05-17 2018-12-26 Fresenius Medical Care Deutschland GmbH Device and method for optimizing the energy consumption in a medical apparatus
US10076283B2 (en) 2013-11-04 2018-09-18 Medtronic, Inc. Method and device to manage fluid volumes in the body
US10537875B2 (en) 2013-11-26 2020-01-21 Medtronic, Inc. Precision recharging of sorbent materials using patient and session data
US10004839B2 (en) 2013-11-26 2018-06-26 Medtronic, Inc. Multi-use sorbent cartridge
US9884145B2 (en) 2013-11-26 2018-02-06 Medtronic, Inc. Parallel modules for in-line recharging of sorbents using alternate duty cycles
US10052612B2 (en) 2013-11-26 2018-08-21 Medtronic, Inc. Zirconium phosphate recharging method and apparatus
US9895477B2 (en) 2013-11-26 2018-02-20 Medtronic, Inc. Detachable module for recharging sorbent materials with optional bypass
US9943780B2 (en) 2013-11-26 2018-04-17 Medtronic, Inc. Module for in-line recharging of sorbent materials with optional bypass
CN105992552B (en) 2013-11-27 2019-06-18 美敦力公司 Accurate dialysis monitoring and synchronization system
CN104740707B (en) * 2013-12-30 2018-06-01 甘布罗伦迪亚股份公司 Dialysis machine, the method for controlling dialysis machine
ES2864727T3 (en) 2014-04-29 2021-10-14 Outset Medical Inc Dialysis system and methods
US20150317899A1 (en) 2014-05-01 2015-11-05 Covidien Lp System and method for using rfid tags to determine sterilization of devices
GB201409796D0 (en) 2014-06-02 2014-07-16 Quanta Fluid Solutions Ltd Method of heat sanitization of a haemodialysis water circuit using a calculated dose
EP3160532B1 (en) 2014-06-24 2019-09-18 Medtronic Inc. A urease introduction system for replenishing urease in a sorbent cartridge
WO2015199768A1 (en) 2014-06-24 2015-12-30 Medtronic, Inc. Stacked sorbent assembly
US10016553B2 (en) 2014-06-24 2018-07-10 Medtronic, Inc. Replenishing urease in dialysis systems using a urease introducer
EP3160533B1 (en) 2014-06-24 2020-08-12 Medtronic Inc. Sorbent pouch
US10172991B2 (en) 2014-06-24 2019-01-08 Medtronic, Inc. Modular dialysate regeneration assembly
WO2015199764A1 (en) 2014-06-24 2015-12-30 Medtronic, Inc. Replenishing urease in dialysis systems using urease pouches
US20160101225A1 (en) * 2014-10-13 2016-04-14 Purewater Therapeutics, LLC Dialysis system
US10098993B2 (en) 2014-12-10 2018-10-16 Medtronic, Inc. Sensing and storage system for fluid balance
US9895479B2 (en) 2014-12-10 2018-02-20 Medtronic, Inc. Water management system for use in dialysis
US10874787B2 (en) 2014-12-10 2020-12-29 Medtronic, Inc. Degassing system for dialysis
US9713665B2 (en) 2014-12-10 2017-07-25 Medtronic, Inc. Degassing system for dialysis
CN104437099B (en) * 2014-12-19 2016-09-07 山东中保康医疗器具有限公司 The detection method of single use filter for removing white blood cell film material water for cleaning
JP6805165B2 (en) 2015-04-07 2020-12-23 ネクステージ メディカル インコーポレイテッド Blood processing device priming set
WO2016207206A1 (en) 2015-06-25 2016-12-29 Gambro Lundia Ab Medical device system and method having a distributed database
DE102015114004B4 (en) * 2015-08-24 2020-07-02 Sartorius Stedim Biotech Gmbh Disposable filtration device
US10434239B1 (en) * 2015-09-11 2019-10-08 Mallinckrodt Hospital Products IP Limited Centrifuge system and method with component tracking
GB2543801A (en) 2015-10-28 2017-05-03 Quanta Fluid Solutions Ltd Dialysis machine and ultrafiltration
CN105288764B (en) * 2015-10-29 2017-11-07 马德升 A kind of liquid dispensing device for haemodialysis
WO2017078965A1 (en) 2015-11-06 2017-05-11 Medtronic, Inc Dialysis prescription optimization for decreased arrhythmias
US20180353672A1 (en) * 2015-12-04 2018-12-13 Qidni Labs, Inc. Implantable renal replacement therapy
GB201523104D0 (en) 2015-12-30 2016-02-10 Quanta Fluid Solutions Ltd Dialysis machine
MX2018008877A (en) 2016-01-22 2018-09-21 Baxter Int Sterile solutions product bag.
NZ743477A (en) * 2016-01-22 2019-03-29 Baxter Healthcare Sa Method and machine for producing sterile solution product bags
US10874790B2 (en) 2016-08-10 2020-12-29 Medtronic, Inc. Peritoneal dialysis intracycle osmotic agent adjustment
US10994064B2 (en) 2016-08-10 2021-05-04 Medtronic, Inc. Peritoneal dialysate flow path sensing
WO2017193073A1 (en) 2016-05-06 2017-11-09 Gambro Lundia Ab Systems and methods for peritoneal dialysis having point of use dialysis fluid preparation including mixing and heating therefore
EP3500317B1 (en) 2016-08-19 2022-02-23 Outset Medical, Inc. Peritoneal dialysis system and methods
US11013843B2 (en) 2016-09-09 2021-05-25 Medtronic, Inc. Peritoneal dialysis fluid testing system
US10981148B2 (en) 2016-11-29 2021-04-20 Medtronic, Inc. Zirconium oxide module conditioning
WO2018114346A1 (en) 2016-12-21 2018-06-28 Gambro Lundia Ab Medical device system including information technology infrastructure having secure cluster domain supporting external domain
GB201622119D0 (en) 2016-12-23 2017-02-08 Quanta Dialysis Tech Ltd Improved valve leak detection system
US11167070B2 (en) 2017-01-30 2021-11-09 Medtronic, Inc. Ganged modular recharging system
CN106902640B (en) * 2017-02-08 2018-03-09 中国环境科学研究院 A kind of full-automatic solution dialysis experimental provision
GB201703048D0 (en) 2017-02-24 2017-04-12 Quanta Dialysis Tech Ltd Testing rotor engagement of a rotary peristaltic pump
US11110214B2 (en) * 2017-04-07 2021-09-07 Fresenius Medical Care Holdings, Inc. Methods and systems for measuring and heating dialysate
US10960381B2 (en) 2017-06-15 2021-03-30 Medtronic, Inc. Zirconium phosphate disinfection recharging and conditioning
USD907211S1 (en) 2017-09-28 2021-01-05 Quanta Dialysis Technologies Ltd. Dialysis machine
US11278654B2 (en) 2017-12-07 2022-03-22 Medtronic, Inc. Pneumatic manifold for a dialysis system
US10881347B2 (en) 2017-12-29 2021-01-05 Fresenius Medical Care Holdings, Inc. Closed loop dialysis treatment using adaptive ultrafiltration rates
US11033667B2 (en) 2018-02-02 2021-06-15 Medtronic, Inc. Sorbent manifold for a dialysis system
US11110215B2 (en) 2018-02-23 2021-09-07 Medtronic, Inc. Degasser and vent manifolds for dialysis
CA3092575A1 (en) 2018-02-28 2019-09-06 Nxstage Medical, Inc. Fluid preparation and treatment devices, methods, and systems
EP3560577A1 (en) 2018-04-25 2019-10-30 Gambro Lundia AB Apparatus and method for testing integrity of an ultrafilter membrane
US20190381232A1 (en) * 2018-06-15 2019-12-19 Fresenius Medical Care Holdings, Inc. Automatic Priming and Scheduling for Dialysis Systems
US11213616B2 (en) 2018-08-24 2022-01-04 Medtronic, Inc. Recharge solution for zirconium phosphate
US11806457B2 (en) 2018-11-16 2023-11-07 Mozarc Medical Us Llc Peritoneal dialysis adequacy meaurements
US11806456B2 (en) 2018-12-10 2023-11-07 Mozarc Medical Us Llc Precision peritoneal dialysis therapy based on dialysis adequacy measurements
CN112516798A (en) * 2020-11-16 2021-03-19 江苏汉光生物工程有限公司 Method for purifying erythritol fermentation liquor
US11850344B2 (en) 2021-08-11 2023-12-26 Mozarc Medical Us Llc Gas bubble sensor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220598A1 (en) * 2002-05-24 2003-11-27 Don Busby Automated dialysis system

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2995334A (en) 1959-06-08 1961-08-08 Becton Dickinson Co Clysis assembly
US3034085A (en) 1959-12-09 1962-05-08 Whirlpool Co Combined fluid and electrical connector
US3100486A (en) 1960-08-22 1963-08-13 Becton Dickinson Co Parenteral set assembly and clamp for use therein
US3252124A (en) 1961-03-10 1966-05-17 Wago Klemmenwerk G M B H Push-in connector
US3103335A (en) 1961-03-28 1963-09-10 Resiflex Lab Inc Unitary clamp means for flexible tubes
US3709365A (en) 1970-06-01 1973-01-09 Squibb & Sons Inc Disposable pharmaceutical sterile closures
JPS4941276Y1 (en) 1970-12-29 1974-11-12
US4370983A (en) * 1971-01-20 1983-02-01 Lichtenstein Eric Stefan Computer-control medical care system
JPS5622296Y2 (en) 1972-07-15 1981-05-26
IT984697B (en) * 1973-05-25 1974-11-20 Bellco Spa CONCENTRATE DILUTER FOR THE PREPARATION OF THE DIA LYSIS LIQUID IN ARTIFICIAL KIDNEYS
US4059512A (en) * 1974-12-27 1977-11-22 Preventive Systems, Inc. Process for removing endotoxin from biological fluids
DE2613281C2 (en) 1976-03-29 1984-12-20 Günter van Dr.med. 4000 Düsseldorf Endert Double lumen catheter
DE2703087C2 (en) 1977-01-26 1984-11-29 Günter van Dr.med. 4000 Düsseldorf Endert Double lumen catheter
US4246101A (en) 1978-12-28 1981-01-20 Pure Cycle Corporation Water recycling system
US4495067A (en) 1980-12-02 1985-01-22 Tracor, Inc. Apparatus for preparation of infusion grade water
FR2507481B1 (en) 1981-06-16 1985-06-14 Hospal Sodip ARTIFICIAL KIDNEY WITH INTEGRATED CIRCUITS
US4626240A (en) 1981-11-06 1986-12-02 Shiley Incorporated Dual lumen subclavian cannula
AU540708B2 (en) * 1982-01-25 1984-11-29 Mitsubishi Rayon Company Limited Water purifying method and system
US4431545A (en) * 1982-05-07 1984-02-14 Pall Corporation Microporous filter system and process
US4432765A (en) 1982-07-14 1984-02-21 Oscarsson Rolf A Attachment device for medical fluids bag
US4596550A (en) 1982-09-24 1986-06-24 Baxter Travenol Laboratories, Inc. Method and apparatus for ultrafiltration measurement in a two pump dialysis system
ATE22013T1 (en) * 1983-03-01 1986-09-15 Sartorius Gmbh DEVICE FOR PREPARATION OF MEDICAL INFUSION SOLUTIONS.
DE8305713U1 (en) 1983-03-01 1985-12-12 Sartorius GmbH, 3400 Göttingen Device for the preparation of medical infusion solutions for the "artificial kidney"
DE3313421C2 (en) * 1983-04-13 1985-08-08 Fresenius AG, 6380 Bad Homburg Device for regulating the ultrafiltration rate in devices for extracorporeal cleaning of blood
CH658636A5 (en) 1983-11-02 1986-11-28 Serge Michielin WATERPROOF SEALING DEVICE ADAPTABLE TO ANY FORM OF PACKAGING OR APPARATUS CONTAINING FLUIDS.
US4564132A (en) 1984-02-24 1986-01-14 Scholle Corporation Fluid dispensing assembly
US4661246A (en) 1984-10-01 1987-04-28 Ash Medical Systems, Inc. Dialysis instrument with dialysate side pump for moving body fluids
DE3444671A1 (en) * 1984-12-07 1986-06-12 Fresenius AG, 6380 Bad Homburg HAEMODIA FILTRATION DEVICE
US4643389A (en) 1984-12-27 1987-02-17 American Hospital Supply Corporation Tubing occlusion clip
US4784495A (en) 1987-02-06 1988-11-15 Gambro Ab System for preparing a fluid intended for a medical procedure by mixing at least one concentrate in powder form with water
DE3709432A1 (en) * 1987-03-21 1988-10-06 Fresenius Ag CAPILLARY FILTER ARRANGEMENT FOR THE STERILIZATION OF LIQUID MEDIA
US5079236A (en) 1987-05-27 1992-01-07 Hyal Pharmaceutical Corporation Pure, sterile, pyrogen-free hyaluronic acid formulations their methods of preparation and methods of use
US5511875A (en) * 1990-02-19 1996-04-30 Gambro Ab System for the preparation of a fluid concentrate intended for medical use
FR2660866B1 (en) 1990-04-13 1992-06-12 Hogamed PROCESS AND DEVICE FOR PREPARING A SUBSTITUTION LIQUID.
US5139483A (en) 1990-05-07 1992-08-18 Ryan Medical, Inc. Medical intravenous administration line connector
US5102399A (en) 1990-06-11 1992-04-07 Chu Young K Clinical tube holder valve assembly and method
US5032265A (en) 1990-06-20 1991-07-16 Millipore Corporation Method and system for producing sterile aqueous solutions
US5221483A (en) 1990-06-29 1993-06-22 Coulter Corporation Process and apparatus for removal of DNA, viruses and endotoxins
EP0544839A4 (en) 1990-08-20 1993-08-11 Abbott Laboratories Medical drug formulation and delivery system
US5250041A (en) 1992-01-16 1993-10-05 Fresenius Usa, Inc. Tubing administration set for use in peritoneal dialysis
US5484431A (en) 1991-01-29 1996-01-16 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration System for creating at a site, remote from a sterile environment, a parenteral solution
US5336165A (en) 1991-08-21 1994-08-09 Twardowski Zbylut J Artificial kidney for frequent (daily) Hemodialysis
US5308333A (en) * 1991-12-06 1994-05-03 Baxter International Inc. Air eliminating intravenous infusion pump set
US5259954A (en) 1991-12-16 1993-11-09 Sepratech, Inc. Portable intravenous solution preparation apparatus and method
US5536412A (en) * 1992-02-06 1996-07-16 Hemocleanse, Inc. Hemofiltration and plasmafiltration devices and methods
US5368555A (en) 1992-12-29 1994-11-29 Hepatix, Inc. Organ support system
FI941336A (en) * 1993-03-23 1994-09-24 Diomedes Oy A patch that acts as a dispenser
US5622626A (en) 1994-04-15 1997-04-22 Pall Corporation Multiple compartment filter and method for processing parenteral fluid
DE4422100C1 (en) 1994-06-24 1995-12-14 Fresenius Ag Flexible medical packaging unit for haemodialysis
ES2139783T5 (en) 1994-07-13 2005-10-16 Fresenius Medical Care Deutschland Gmbh PREPARATION OF SUBSTITUTE LIQUID IN A HEMOFILTRATED OR FILTERED HEMO-DAY APPLIANCE.
FR2723002B1 (en) 1994-07-26 1996-09-06 Hospal Ind DEVICE AND METHOD FOR PREPARING A FILTRATION PROCESSING LIQUID
JPH0852196A (en) 1994-08-09 1996-02-27 Material Eng Tech Lab Inc Transfusion container having connecting port for medicine
SE503198C2 (en) * 1994-09-20 1996-04-15 Gambro Ab Method and apparatus for central preparation of a salt concentrate and method for disinfecting the apparatus and containers intended for the apparatus
US5782762A (en) 1994-10-27 1998-07-21 Wake Forest University Method and system for producing interactive, three-dimensional renderings of selected body organs having hollow lumens to enable simulated movement through the lumen
US5591344A (en) 1995-02-13 1997-01-07 Aksys, Ltd. Hot water disinfection of dialysis machines, including the extracorporeal circuit thereof
US5932110A (en) 1995-02-13 1999-08-03 Aksys, Ltd. Dialysate conductivity adjustment in a batch dialysate preparation system
IT1275427B (en) * 1995-05-16 1997-08-07 Bracco Spa PROCESS FOR THE DEPIROGENATION OF INJECTABLE PHARMACEUTICAL SOLUTIONS
US5972225A (en) * 1996-05-07 1999-10-26 Cook Imaging Corporation Process for remediating endotoxin-contaminated bulk non-ionic contrast media
SE510127C2 (en) 1996-06-13 1999-04-19 Althin Medical Ab Disposable Hemodia Filtration Kit
US5707038A (en) 1996-10-23 1998-01-13 Cocatre-Zilgien; Jan H. Hinged kink valve
DE19700466A1 (en) 1997-01-09 1998-07-16 Polaschegg Hans Dietrich Dr Hemodiafiltration device and method
DE19704564A1 (en) 1997-02-07 1998-08-13 Polaschegg Hans Dietrich Dr Flushing equipment for extracorporeal blood-treatment circuit
US6106723A (en) 1997-02-10 2000-08-22 Grandics; Peter Method for removing pyrogens from dialysate
US6595943B1 (en) 1997-02-14 2003-07-22 Nxstage Medical, Inc. Systems and methods for controlling blood flow and waste fluid removal during hemofiltration
EP1235613B1 (en) * 1997-02-14 2011-02-09 NxStage Medical, Inc. Fluid processing systems using extracorporeal fluid flow panels oriented within a cartridge
US20010016699A1 (en) 1997-02-14 2001-08-23 Jeffrey H. Burbank Hemofiltration system
US6638477B1 (en) 1997-02-14 2003-10-28 Nxstage Medical, Inc. Fluid replacement systems and methods for use in hemofiltration
US6830553B1 (en) * 1997-02-14 2004-12-14 Nxstage Medical, Inc. Blood treatment systems and methods that maintain sterile extracorporeal processing conditions
US6852090B2 (en) 1997-02-14 2005-02-08 Nxstage Medical, Inc. Fluid processing systems and methods using extracorporeal fluid flow panels oriented within a cartridge
US6638478B1 (en) 1997-02-14 2003-10-28 Nxstage Medical, Inc. Synchronized volumetric fluid balancing systems and methods
US6589482B1 (en) * 1997-02-14 2003-07-08 Nxstage Medical, Inc. Extracorporeal circuits for performing hemofiltration employing pressure sensing without an air interface
US5919357A (en) * 1997-05-20 1999-07-06 United States Filter Corporation Filter cartridge assembly
FI103106B (en) 1997-11-12 1999-04-30 Steris Europe Inc Process and apparatus for producing clean water
DE19801768C2 (en) 1998-01-19 2001-04-19 Fresenius Medical Care De Gmbh Method and device for providing operational dialysis fluid
EP1061961B1 (en) 1998-01-23 2004-12-01 ViaCirQ, Inc. Apparatuses and processes for whole-body hyperthermia
US7004924B1 (en) 1998-02-11 2006-02-28 Nxstage Medical, Inc. Methods, systems, and kits for the extracorporeal processing of blood
US6582385B2 (en) * 1998-02-19 2003-06-24 Nstage Medical, Inc. Hemofiltration system including ultrafiltrate purification and re-infusion system
FR2778335B1 (en) 1998-05-06 2001-02-09 Dominique Lambert RADIO FREQUENCY READ / WRITE LABEL POCKET FOR COLLECTION, STORAGE AND TRANSPORT OF BLOOD OR BLOOD COMPONENTS
US6287516B1 (en) * 1998-07-10 2001-09-11 Immunocept, L.L.C. Hemofiltration systems, methods, and devices used to treat inflammatory mediator related disease
DE19832451C1 (en) * 1998-07-18 1999-08-26 Fresenius Medical Care De Gmbh Method of checking the orderly exchange of a used filter in an arrangement for extracorporal blood treatment
US6183637B1 (en) 1998-07-23 2001-02-06 Seh America, Inc. Resin trap device for use in ultrapure water systems and method of purifying water using same
US6331252B1 (en) * 1998-07-31 2001-12-18 Baxter International Inc. Methods for priming a blood compartment of a hemodialyzer
US6729369B2 (en) 1998-07-31 2004-05-04 Chata Biosystems, Inc. Vessel for containing/transporting a fluent substance
US6044691A (en) 1998-08-26 2000-04-04 Aksys, Ltd. Blood tubing set integrity tests for extracorporeal circuits
JP2000088297A (en) * 1998-09-17 2000-03-31 Hitachi Ltd Ice heat storage type air-conditioning device and ice heat storage tank
US6626857B1 (en) * 1998-11-19 2003-09-30 Tomio Ohta Extracorporeal circulation device and method for isolation temperature control method
EP1157709B1 (en) * 1999-02-10 2012-05-30 Tomio Ohta Bloodless treating device
US6254567B1 (en) * 1999-02-26 2001-07-03 Nxstage Medical, Inc. Flow-through peritoneal dialysis systems and methods with on-line dialysis solution regeneration
US6274103B1 (en) * 1999-03-26 2001-08-14 Prismedical Corporation Apparatus and method for preparation of a peritoneal dialysis solution
AU759854C (en) 1999-04-23 2004-01-08 Cytopherx, Inc. Extracorporeal circuit and related methods
US6406631B1 (en) 1999-07-30 2002-06-18 Nephros, Inc. Two stage diafiltration method and apparatus
US6284142B1 (en) 1999-09-03 2001-09-04 Baxter International Inc. Sensing systems and methods for differentiating between different cellular blood species during extracorporeal blood separation or processing
US6428518B1 (en) 1999-11-05 2002-08-06 Tandem Medical Medication delivery container
US6776912B2 (en) 1999-12-23 2004-08-17 Membrana Gmbh Hemodiafiltration system and method
ATE358527T1 (en) 2000-01-11 2007-04-15 Nephros Inc BLOOD PURIFICATION SYSTEM
US6787040B2 (en) 2000-05-16 2004-09-07 Immunocept, L.L.C. Method and system for colloid exchange therapy
EP1322352A4 (en) 2000-09-27 2010-06-16 Sorin Group Usa Inc Disposable cartridge for a blood perfusion system
EP1343576B1 (en) * 2000-10-19 2007-02-21 Nephros, Inc. Method and apparatus for generating a sterile infusion fluid
CA2430575C (en) * 2000-12-08 2009-04-07 Nephros, Inc. Valve mechanism for infusion fluid systems
EP1368108A4 (en) 2001-02-07 2006-05-31 Nephros Inc Method and apparatus for a hemodiafiltration delivery module
WO2002066099A2 (en) 2001-02-16 2002-08-29 Piedmont Renal Clinics, P.A. Automated peritoneal dialysis system and process with in-line sterilization of dialysate
US6573734B2 (en) 2001-05-08 2003-06-03 The Board Of Trustees Of The University Of Illinois Integrated thin film liquid conductivity sensor
CN100351006C (en) 2001-05-14 2007-11-28 沃特海尔斯国际公司 Powered sterile solution device
ES2498966T3 (en) 2001-05-21 2014-09-26 Scott Laboratories, Inc. RF-ID tag for a medical container
US20050020960A1 (en) 2001-05-24 2005-01-27 Brugger James M. Blood treatment cartridge and blood processing machine with slot
WO2002102722A1 (en) 2001-06-19 2002-12-27 Prismedical Corporation Medical grade water production system
US6572576B2 (en) 2001-07-07 2003-06-03 Nxstage Medical, Inc. Method and apparatus for leak detection in a fluid line
US6649063B2 (en) 2001-07-12 2003-11-18 Nxstage Medical, Inc. Method for performing renal replacement therapy including producing sterile replacement fluid in a renal replacement therapy unit
US20030010717A1 (en) * 2001-07-13 2003-01-16 Nx Stage Medical, Inc. Systems and methods for handling air and/or flushing fluids in a fluid circuit
US6743193B2 (en) 2001-07-17 2004-06-01 Nx Stage Medical, Inc. Hermetic flow selector valve
JP4370552B2 (en) 2001-09-14 2009-11-25 ニプロ株式会社 Chemical solution injection port
US20030051767A1 (en) 2001-09-19 2003-03-20 Unilever Home And Personal Care Usa Package and system
US20030236481A1 (en) 2002-01-07 2003-12-25 Jeffrey Burbank Hemofiltration filter with high membrane utilization effectiveness
US20030130606A1 (en) * 2002-01-07 2003-07-10 Tuck Joseph E. Blood treatment replacement fluid using infusible fluids in combination
EP2357016B1 (en) 2002-01-31 2016-04-20 Fenwal, Inc. Irreversibly closable flow control clamp
US6962575B2 (en) 2002-02-05 2005-11-08 Yale University Single access dialysis needle
US20030168389A1 (en) 2002-02-15 2003-09-11 Astle Robert E. System for monitoring the performance of fluid treatment cartridges
US6745903B2 (en) 2002-03-14 2004-06-08 Peter Grandics Methods for the on-line, on-demand preparation of sterile, water-for-injection grade water
WO2003086629A1 (en) 2002-04-12 2003-10-23 Ionics, Incorporated Ion exchange regeneration and upw treatment system
US6691058B2 (en) 2002-04-29 2004-02-10 Hewlett-Packard Development Company, L.P. Determination of pharmaceutical expiration date
AU2003237403A1 (en) * 2002-06-06 2003-12-22 Nxstage Medical, Inc. Last-chance quality check and/or air/pyrogen filter for infusion systems
US6982038B2 (en) 2002-06-14 2006-01-03 Medtronic, Inc. Centrifuge system utilizing disposable components and automated processing of blood to collect platelet rich plasma
WO2005068043A1 (en) 2004-01-07 2005-07-28 Nxstage Medical, Inc. Filtration system for preparation of fluids for medical applications
US9700663B2 (en) 2005-01-07 2017-07-11 Nxstage Medical, Inc. Filtration system for preparation of fluids for medical applications
DE602004021672D1 (en) 2003-01-07 2009-08-06 Nxstage Medical Inc CHARGE FILTRATION SYSTEM FOR PRODUCING A STERILE SPARELIFE FLUID FOR NURSING TREATMENTS
US20080210606A1 (en) 2004-01-07 2008-09-04 Jeffrey Burbank Filtration System Preparation of Fluids for Medical Applications
WO2004066121A2 (en) 2003-01-15 2004-08-05 Nxstage Medical Inc. Waste balancing for extracorporeal blood treatment systems
US20050277805A1 (en) 2003-03-06 2005-12-15 Hatton Daniel M Fecal incontinence assistance device
US20040186415A1 (en) 2003-03-20 2004-09-23 Burbank Jeffrey H. Blood circuit with leak-safe features
DE10328435B3 (en) 2003-06-25 2005-03-24 Fresenius Medical Care Deutschland Gmbh Device for extracorporeal blood treatment with a device for checking a sterile filter and method for checking a sterile filter of an extracorporeal blood treatment device
US20050103717A1 (en) 2003-11-13 2005-05-19 United States Filter Corporation Water treatment system and method
US7393450B2 (en) 2003-11-26 2008-07-01 Silveri Michael A System for maintaining pH and sanitizing agent levels of water in a water feature
US20050171501A1 (en) 2004-02-03 2005-08-04 Thomas Kelly Intravenous solution producing systems and methods
JP4734343B2 (en) 2005-01-07 2011-07-27 エヌエックスステージ・メディカル・インコーポレイテッド Purification system for solution preparation for medical applications
ATE477438T1 (en) 2006-04-07 2010-08-15 Nxstage Medical Inc HOSE CLAMP FOR MEDICAL APPLICATIONS
US9758388B2 (en) 2009-06-07 2017-09-12 Nufiltration Ltd. Device and method for water filtration using recycled medical filters

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220598A1 (en) * 2002-05-24 2003-11-27 Don Busby Automated dialysis system

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100621A1 (en) * 2015-12-11 2017-06-15 Nxstage Medical, Inc. Fluid line connector devices methods and systems
EP3386561A4 (en) * 2015-12-11 2019-07-10 NxStage Medical Inc. Fluid line connector devices methods and systems
US11504517B2 (en) 2015-12-11 2022-11-22 Nxstage Medical, Inc. Fluid line connector devices methods and systems
US10406269B2 (en) 2015-12-29 2019-09-10 Fresenius Medical Care Holdings, Inc. Electrical sensor for fluids
US10617809B2 (en) 2015-12-29 2020-04-14 Fresenius Medical Care Holdings, Inc. Electrical sensor for fluids
US10716884B2 (en) 2015-12-29 2020-07-21 Fresenius Medical Care Holdings, Inc. Electrical sensor for fluids

Also Published As

Publication number Publication date
US20120305481A1 (en) 2012-12-06
WO2004062710A3 (en) 2004-10-21
US20080053905A9 (en) 2008-03-06
US20110240547A1 (en) 2011-10-06
US9388059B2 (en) 2016-07-12
US20130327691A1 (en) 2013-12-12
US8679348B2 (en) 2014-03-25
US20170266360A1 (en) 2017-09-21
ATE434454T1 (en) 2009-07-15
US7976711B2 (en) 2011-07-12
US10420871B2 (en) 2019-09-24
EP1592494B1 (en) 2009-06-24
US20130264250A1 (en) 2013-10-10
US20090211975A1 (en) 2009-08-27
EP1592494A2 (en) 2005-11-09
US20070007208A1 (en) 2007-01-11
US7544300B2 (en) 2009-06-09
US20120325696A1 (en) 2012-12-27
US7749393B2 (en) 2010-07-06
US20100228177A1 (en) 2010-09-09
WO2004062710A2 (en) 2004-07-29
US8202420B2 (en) 2012-06-19
US8545428B2 (en) 2013-10-01
US8460558B2 (en) 2013-06-11
DE602004021672D1 (en) 2009-08-06
US20110186521A1 (en) 2011-08-04
EP1592494A4 (en) 2006-07-26

Similar Documents

Publication Publication Date Title
US7544300B2 (en) Batch filtration system for preparation of sterile fluid for renal replacement therapy
US11446417B2 (en) Filtration system for preparation of fluids for medical applications
US8192387B2 (en) Last-chance quality check and/or air/pathogen filter for infusion systems
US20210316056A1 (en) Systems and methods for peritoneal dialysis having point of use dialysis fluid preparation using water accumulator and disposable set
US20230302209A1 (en) Filtration System for Preparation of Fluids for Medical Applications
US4338190A (en) Peritoneal artificial kidney
GB2310617A (en) Modular home dialysis system

Legal Events

Date Code Title Description
AS Assignment

Owner name: GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTR

Free format text: SECURITY INTEREST;ASSIGNOR:NXSTAGE MEDICAL, INC.;REEL/FRAME:033123/0836

Effective date: 20140609

AS Assignment

Owner name: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR

Free format text: ASSIGNMENT OF INTELLECTUAL PROPERTY SECURITY AGREEMENT;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING AGENT;REEL/FRAME:037112/0376

Effective date: 20151113

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: NXSTAGE MEDICAL, INC., MASSACHUSETTS

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CAPITAL ONE, NATIONAL ASSOCIATION (AS SUCCESSOR BY MERGER TO HEALTHCARE FINANCIAL SOLUTIONS, LLC);REEL/FRAME:048407/0865

Effective date: 20190221